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Abstract 
Nuclear erythroid 2 p45-related factor 2 (Nrf2) is a master regulator of oxidative 
defence, by controlling the expression of a battery of antioxidant enzyme proteins during 
stressful stimuli. Although Nrf2 is widely expressed, its role in regulating skeletal muscle 
phenotype remains to be elucidated. We sought to investigate the impact of Nrf2 on 
exercise-induced mitochondrial adaptations and aging using wild-type (WT) and 
knockout (KO) mice at 3 and 12 months of age. Basally, our results indicate that Nrf2 is 
important for mitochondrial respiration and skeletal muscle performance. Although Nrf2 
did not impact mitochondrial content under quiescent conditions, it was necessary for 
mitochondrial content adaptations that occur in response to training. However, we also 
showed that exercise was capable of rescuing the initial deficits in respiration and muscle 
performance in animals lacking Nrf2, highlighting the broad cellular signaling benefits of 
exercise training beneficial effects of exercise training.   
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1.1.0 Skeletal muscle structure and function 
 In humans, muscle comprises the largest group of tissues in the body, accounting 
for approximately half of the body’s weight. Skeletal muscle alone comprises ~40% of 
body weight with smooth and cardiac muscle making up the other 10% of the total 
weight. Since skeletal muscle accounts for such a large proportion of total body mass it is 
not surprising that it has a significant contribution to several bodily functions. From a 
mechanical point of view, the primary function of skeletal muscle is to convert chemical 
energy, in the form of adenosine triphosphate (ATP), into mechanical energy to generate 
force, maintain posture and produce movement. From a metabolic perspective, skeletal 
muscle is essential for energy storage, maintenance of blood glucose homeostasis, fatty 
acid oxidation and temperature regulation.  
 The architecture of skeletal muscle is characterized by a very particular and quite 
sophisticated arrangement of muscle fibres. Each individual muscle fibre is comprised of 
specialized contractile elements called myofibrils. Furthermore, each myofibril consists 
of a regular arrangement of highly organized cytoskeletal elements – the thick filament, 
myosin and the thin filament, actin. Despite its unique shape and organization, muscle 
contains many of the same organelles that are present in other cell types. However, there 
is heterogeneity in human skeletal muscle that is characterized by differences in the 
biochemical, mechanical and metabolic phenotypes of individual fibres. The most 
frequently used classification system includes three fibre types: type I (slow, oxidative, 
fatigue-resistant), type IIA (fast, oxidative, intermediate metabolic properties) and type 
IId/x (fastest, glycolytic, fatigable) (123). The oxidative capacity of a fibre is determined 
by the number of mitochondria, the number of capillaries and the amount of myoglobin it 
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contains. Whereas the oxidative capacity of the muscle coincides with the metabolic 
profile of the muscle fibre, the maximum velocity of muscle shortening (fast vs. slow) is 
dependent on the type of myosin heavy chain (MHC) ATPase isoform it possesses (123).  
 A unique feature of skeletal muscle fibres is that they are multinucleated. In 
general, each nucleus within a muscle fibre controls the type of proteins synthesized 
within a specific region of the cell. These regions are commonly referred to as nuclear 
domains, which are highly regulated but not constant in size (6, 138). Furthermore, since 
skeletal muscle is a post-mitotic tissue it cannot be replicated by mitosis when destroyed 
or injured. As such, skeletal muscle contains a group of myogenic precursor cells, called 
satellite cells. These cells reside between the sarcolemma and the basal lamina and 
contribute to muscle growth, repair and regeneration (93, 151).  
1.1.1 Skeletal muscle plasticity and adaptation 
 Skeletal muscle is a highly malleable tissue exhibiting remarkable capabilities in 
its ability to adapt to a number of physiological and pathological conditions. For instance, 
changes in contractile activity induced by alterations in physical activity, muscle disuse 
or aging can have a pronounced effect on the metabolic and morphological characteristics 
of the muscle.  
 Exercise is a potent stimulus and powerful metabolic stressor. Each bout of 
exercise initiates signaling events that alter the expression of a variety of nuclear DNA 
and mitochondrial DNA (mtDNA) gene products, resulting in phenotypic adaptations. 
One of the most dramatic examples of this phenotypic adaptation is the increase in 
mitochondrial volume, which coincides with fatigue-resistance and improvements in 
endurance performance. However, muscle responds to exercise in a training-specific 
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manner. That is, endurance training leads to an increase in oxidative capacity, which is 
mediated by expansion of the mitochondrial reticulum (181), whereas, resistance training 
induces the hypertrophy of muscle fibres to enhance force production (125).  
 In contrast to the beneficial effects elicited with exercise, chronic muscle disuse 
results in marked reductions in mitochondrial content (2, 156) and muscle mass (2, 156). 
Muscle wasting of this nature is largely due to accelerated protein degradation with 
concomitant reductions in protein synthesis (124). Although it has been demonstrated that 
disuse atrophy is largely mediated by the proteasomal (28, 184) and lysosomal systems 
(95), there is also evidence to suggest that apoptosis (2) is another contributing factor. 
Similarly, atrophy is also a defining feature of aging skeletal muscle that contributes to 
progressive weakness and increased frailty. Additionally, aging also provokes phenotypic 
changes in mitochondria, which are attributed to both inactivity and inherent, aging-
induced changes in mitochondrial synthesis and degradation pathways. 
1.1.1.1 Mitochondrial biogenesis  
 Mitochondrial adaptations that occur in response to exercise training are 
commonly referred to as “mitochondrial biogenesis”. This process is typically 
characterized by an increase in mitochondrial content and alterations to the mitochondrial 
ultrastructure. Although this phenomenon has long been established (52) the regulatory 
mechanisms governing this process have only recently been investigated. For instance, a 
current study utilizing a model of chronic contractile activity (CCA) demonstrated 
significant increases in the mitochondrial fusion proteins, Mfn2 and OPA1, with 
concomitant reductions in Drp1, a critical protein involved in mitochondrial fission (60). 
Furthermore, there is evidence to suggest that signaling events promoting mitochondrial 
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remodelling are one of the earliest events to occur in response to an acute bout of 
exercise. For instance, it was shown that a single bout of exercise promoted an increase in 
the membrane interactions between skeletal muscle mitochondria in both the 
subsarcolemmal (SS) and intermyofibrillar (IMF) subfractions (127). Additionally, 
Cartoni et al. (20) revealed that the mRNA expression of Mfn1 and Mfn2 were 
significantly increased 24 hours following an acute bout of exercise. Collectively, these 
results provide a molecular basis for the observed changes in mitochondrial morphology 
and indicate that these alterations are likely initiated following a single bout of exercise. 
 Although mitochondrial biogenesis begins with the putative signaling brought 
about by acute muscle contractions, the final phenotypic adaptation is the cumulative 
result of a complex series of molecular events. These include signaling events to initiate 
biogenesis, the transcription of nuclear and mitochondrial genes, the import of nuclear 
genes into the mitochondria and the assembly of proteins into functional multi-subunit 
complexes (55).  
1.1.1.1.1 PGC-1α 
 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) 
is a transcriptional coactivator that is often regarded as the most significant regulator of 
mitochondrial biogenesis and function. Evidence for this has been supported by gain of 
function experiments in both cultured cells (170, 180) and transgenic mice (84). Since 
PGC-1α is a transcriptional coactivator, it lacks the capacity to bind nuclear DNA 
directly. Rather, it functions by augmenting the activity of transcription factors, such as 
nuclear respiratory factors 1/2 (NRF-1 and NRF-2) (146, 180), and facilitating the 
recruitment of histone-modifying proteins. This in turn, allows for greater accessibility of 
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the transcriptional machinery to DNA for transcription (174). Coactivation of NRF-1 on 
the Tfam promoter (180), a required factor for the transcription of mtDNA, illustrates the 
importance of PGC-1α in the coordinated expression of mitochondrial genes derived 
from both nuclear and mitochondrial genomes. Thus, there is strong evidence to suggest 
that PGC-1α sits at the crux of the regulation of mitochondrial content and function.  
 It is known that a single bout of exercise can elicit changes in the expression of 
factors involved in mitochondrial biogenesis, including PGC-1α. However, repeated 
bouts of exercise over a given period of time results in the progressive increase in PGC-
1α, NRF-1 and Tfam protein expression (11, 45, 61) . These results indicate that these 
factors are not only crucial for the constitutive maintenance of mitochondrial content and 
function but are also critical for mediating the mitochondrial adaptations to exercise. In 
support of this, skeletal muscle-specific overexpression of PGC-1α is sufficient to 
enhance basal mitochondrial content and endurance performance (19). In contrast, PGC-
1α KO mice exhibit impairments in mitochondrial content and function (4). Furthermore, 
skeletal muscle-specific ablation of PGC-1α results in impaired endurance performance, 
which is likely due to alterations in mitochondrial structure and function, as well as 
reduced expression of oxidative fibres (50). Although it is evident that PGC-1α is 
essential for the maintenance of a healthy mitochondrial network, its absolute necessity 
for mediating exercise-induced adaptations is still being questioned. The question arises 
because it has been shown that PGC-1α is not mandatory for training-induced increases 
in mitochondrial proteins, suggesting that other factors other than PGC-1α can exert these 
adaptations (85). However, in contrast to the previous findings, skeletal muscle-specific 
deletion of PGC-1α attenuated the expression of mitochondrial proteins following an 
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endurance training program, demonstrating an impaired adaptive response (40). This 
suggests that there is perhaps a specific role for PGC-1α in mediating the adaptations of 
skeletal muscle to exercise.  
1.1.1.1.2 AMPK  
 As previously mentioned, mitochondrial biogenesis occurs as a result of enhanced 
intracellular signaling that is generated by muscular contraction. Among these signals is 
the increased activation of the metabolic energy sensor AMP-activated protein kinase 
(AMPK). Exercise increases ATP turnover within muscle cells resulting in a decrease in 
the ATP-to-ADP ratio. Consequently, there is also a rise in the formation of AMP which 
is an allosteric activator of AMPK. The enhanced expression of factors favoring 
oxidative metabolism, including PGC-1α, uncoupling protein 3 (UCP3), cytochrome c, 
succinate dehydrogenase and citrate synthase, have been linked with increased AMPK 
activation (13, 62, 68, 179). Moreover, these effects appear to be mediated by AMPK 
regulation of PGC-1α at both the gene and protein levels. For instance, Garcia-Roves et 
al. (39) demonstrated that genetically or pharmacologically enhancing AMPK activation 
resulted in an increase in both PGC-1α mRNA and protein expression. This is likely 
attributed to AMPK augmenting the binding of critical transcription factors to the PGC-
1α promoter (62). Furthermore, AMPK activation increases the phosphorylation of PGC-
1α, a post-translational modification that is important for the induction of PGC-1α 
regulated genes (68). The necessity of AMPK in the regulation of mitochondrial content 
has been bolstered by studies documenting that knocking out the β-subunits of AMPK 
results in reduced mitochondrial content and muscle function, consequently impairing 
8 
 
endurance performance (116). Collectively, these findings highlight the importance of 
AMPK in regulating mitochondrial content.  
1.1.1.1.3 p38 MAPK 
 Map kinases, such as p38, can be activated by a number of stressful stimuli, 
which include cytokines, growth factors, and exercise (23). Through its ability to 
phosphorylate target protein substrates, p38 has the capacity to regulate multiple cellular 
processes. In particular, p38 has been implicated in regulating exercise-induced changes 
in gene expression. For instance, Akimoto et al. (5) demonstrated that an acute bout of 
exercise increased p38 activity which resulted in an increase in PGC-1α mRNA content. 
The increase in PGC-1α transcript is likely attributed to increased gene transcription, 
since overexpression of p38 has been shown to increase PGC-1α promoter activity. 
Furthermore, contractile activity-induced increases in PGC-1α promoter and protein 
activity were attenuated with inhibition of p38 (183). In addition to its ability to regulate 
PGC-1α at the level of transcription, it has also been demonstrated that p38 can 
phosphorylate PGC-1α, thereby augmenting its ability to regulate the expression of 
nuclear genes-encoding mitochondrial proteins (NUGEMPS) (132). Taken together, these 
findings suggest that p38 is highly sensitive to contractile activity-evoked activation, and 
that it is an important signaling kinase for exercise-induced mitochondrial biogenesis.  
1.1.1.1.4 Voluntary running wheel 
 The running wheel is a crucial instrument for the measurement of physical 
activity in laboratory rodents. Since most rodents readily run in wheels, it provides an 
uncomplicated and easily quantifiable measure of physical activity. However, like 
humans, the tendency for rodents to be more or less active is shaped by both genetic and 
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environmental factors. Although the use of the running wheel is often employed to 
research the effects of exercise on metabolism and obesity, it can also be used to induce 
and study physiological adaptations like mitochondrial biogenesis (143). This is made 
possible by the fact that voluntary wheel running can be a prodigious activity. For 
instance, within a 24-hour time-frame it has been demonstrated that rats and mice can run 
a distance of up to 43 and 16 km, respectively (153). Evidently, this is analogous to a 
long slow-distance run performed by a human. Ultimately, voluntary wheel running 
serves as a simplistic model of physical activity which provides researchers with the 
opportunity to study the health benefits associated with moderate exercise.  
1.1.2 Skeletal muscle disuse atrophy 
 Skeletal muscle mass and fibre size vary according to both physiological and 
pathological conditions. An increase in muscle mass, or hypertrophy, is commonly 
observed in response to mechanical overload (synergistic ablation, strength training) or 
anabolic hormonal stimulation. In contrast, a decrease in muscle mass, or atrophy, results 
from aging, starvation, cancer, diabetes, bed rest, loss of neural input or catabolic 
hormonal stimulation. Ultimately, the regulation of skeletal muscle mass is determined 
by protein turnover. That is, the balance between protein synthesis and degradation. 
Although the exact mechanisms mediating muscle atrophy are not completely 
understood, experiments from both human and animal models have concluded that 
disuse-induced muscle atrophy occurs due to both reductions in protein synthesis and 
accelerated rates of protein breakdown (42, 43, 152). This increase in proteolysis is 
largely reflected by the activation of the ubiquitin proteasome and autophagy systems 
(15, 28, 82, 144). Although muscle atrophy is characterized by the net loss of myofibrillar 
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and sarcoplasmic proteins, a preferential loss of myofibrillar proteins is a hallmark of 
disuse-induced muscle wasting (108).  
1.1.2.1 Ubiquitin-Proteasome System 
 In the ubiquitin-proteasome system (UPS), proteins are targeted for degradation 
by the 26S proteasome. This is accomplished by the covalent attachment of ubiquitin 
molecules onto the target protein. The E3 ubiquitin ligase enzymes are the rate-limiting 
step in the ubiquitination process since they bind the protein substrate and catalyze the 
movement of the ubiquitin from the E2 enzyme onto the substrate. Thus, this step is 
crucial and necessary for the subsequent proteasomal-dependent degradation. Among the 
many E3 ubiquitin ligases, only a few have been found to regulate the atrophy process 
and to be markedly induced under conditions promoting atrophy.  
 The pioneering studies by Goldberg (44) and Glass (16) had a significant impact 
on our understanding of muscle atrophy and the associated profiling of gene expression. 
They were the first to identify Atrogin-1/MAFbx and MuRF1, two E3’s that are 
specifically expressed in smooth and striated muscle that are markedly induced in 
response to an atrophy-inducing stressor. Mice deficient for either MuRF1 or MAFbx 
genes were more resistant to disuse-related atrophy. This was exhibited by a 56% and 
36% muscle sparing effect in the MAFbx and MuRF1 KO mice, respectively, following 
14 days of denervation (16). Interestingly, these two enzymes appear to exert their effects 
differently. Currently, it has been demonstrated that MuRF1 targets several structural 
proteins, including troponin I (73), myosin heavy chains (26), actin (129), myosin 
binding protein C and myosin light chains 1 and 2 (28). In contrast, the substrates 
identified for MAFbx are largely involved in growth-related processes or survival 
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pathways. For instance MAFbx promotes the degradation of MyoD (167), a key muscle 
transcription factor, and eIF3-f, an important activator of protein synthesis.  
 Another E3 ligase that has attracted some attention in mediating disuse atrophy is 
TRAF6. Notably, TRAF6 KO mice are more resistant to muscle loss that is induced by 
denervation (121) and starvation (120). These protective effects may be partially 
explained by the reduced expression of both MuRF1 and MAFbx with TRAF6 inhibition. 
Moreover, it appears that the optimal activation of JNK, AMPK, FOXO3 and NF-κB 
pathways are partially dependent on the presence of TRAF6 (120). Therefore, the effects 
on both FOXO3 and NF-κB signaling may explain where there is a reduction in MuRF1 
and MAFbx expression in the KO animals. Collectively, these findings provide evidence 
for the critical role of the UPS in mediating skeletal muscle atrophy.  
1.1.2.2 Autophagy-Lysosome System 
 Autophagy mediates the bulk degradation of cytoplasmic components, accounting 
for the degradation of most long-lived proteins, including organelles. Ultimately, these 
are sequestered by double-membrane vesicles, called autophagosomes, to the lysosome 
for cellular digestion. Several years ago it was demonstrated that autophagy is active in 
muscle cells during catabolic conditions (32, 148). Moreover, using transgenic mice 
expressing LC3 fused with GFP; Mizushima et al. (103) documented the activation of the 
autophagy system during fasting in skeletal muscle. Furthermore, electron microscopic 
and biochemical studies have also demonstrated that autophagy is induced in response to 
denervation (38). However, this effect appears to be partially dependent on the presence 
of PGC-1α since animals lacking PGC-1α were shown to have an attenuation in the 
induction of autophagy in response to denervation (168).  
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 The regulation of autophagy is not only organ-dependent (103) but also appears to 
differ between stimuli. That is, denervation-induced atrophy shows a slower pace of 
autophagy when compared with fasting-mediated atrophy. It is thought that this 
discrepancy is partially mediated by Runx1, which is upregulated during denervation. 
Furthermore, the importance of Runx1 for the preservation of muscle mass is highlighted 
by the myofibrillar disorganization and excessive autophagy that occurs with denervation 
in response to Runx1 inhibition (177). These results indicate that Runx1 is crucial for 
preventing excessive muscle wasting due to hyperactivation of autophagy.  
 Although it is understood that the autophagy-lysosome and ubiquitin proteasome 
systems are coordinately regulated (95, 184), their relative contribution to organelle 
remodelling, protein breakdown and muscle atrophy remains to be determined.  
1.1.3 Aging 
 Loss of strength and mass, or sarcopenia, is a defining feature of aging skeletal 
muscle and is thought to be the precipitating factor contributing to impairments in 
mobility, increased risk of frailty, disability and even death (30). Although the etiology of 
sarcopenia is multifactorial, several studies have found evidence for reductions in 
mitochondrial content and function in aging muscle (21, 47, 128). Aberrant mitochondrial 
function can be detrimental since this can potentially result in ROS-induced oxidative 
damage to macromolecules, including those within the mitochondrion (i.e. mtDNA and 
ETC complexes). This in turn, can lead to additional mitochondrial dysfunction and 
further elevations in ROS resulting in a “vicious cycle” scenario that can ultimately 
contribute to cell death and sarcopenia (18, 37). Typically increases in ROS are mitigated 
by an intracellular antioxidant response that is largely controlled by the transcription 
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factor Nrf2. However, it has been reported that there is a significant reduction in Nrf2 
nuclear expression in elderly humans leading a sedentary lifestyle (141). Moreover, 
disruption of Nrf2 appears to induce oxidative stress resulting in greater ubiquitination, 
lipid peroxidation and pro-apoptotic signaling in the aged skeletal muscle of Nrf2 KO 
animals (101). These results indicate that the loss of Nrf2 can exacerbate the aging 
phenotype and augment the signaling of skeletal muscle degradation pathways upon 
aging.  
Previously, it has been shown that autophagy is required for the maintenance of 
muscle mass (97). However, there are several studies indicating that this process is 
impaired with aging (70, 82), which likely contributes to the sarcopenic phenotype. 
Compounding this issue further is the reduced capacity for generation of new 
mitochondria. Specifically, aged animals have a compromised ability to augment 
mitochondrial biogenesis in response to both endurance training (14) and chronic 
electrical stimulation (90, 91) . This impairment likely coincides with the reduced 
expression (21) and attenuated induction of PGC-1α (14), in addition to increased 
degradation of precursor proteins destined for import into the mitochondria (58).  
 In addition to its role in maintaining mitochondrial content and health, several 
lines of evidence have also linked PGC-1α with muscle maintenance. For instance, Brault 
et al. (17) demonstrated that overexpression of PGC-1α inhibited muscle atrophy induced 
by denervation. Moreover, in the context of aging, Wenz et al. (178) demonstrated that 
muscle-specific overexpression of PGC-1α protected aging animals from sarcopenia and 
metabolic disease.  
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 Although the loss in muscle mass observed with aging culminates from a number 
of combined factors, there is certainly strong evidence to indicate that mitochondria and 
its associated machinery serve as a nexus point for modulating a wide range of cellular 
functions and signaling pathways that affect the aging phenotype. Understanding these 
mechanisms is important for the development of therapeutic strategies designed to 
increase the health and vitality of the elderly.   
1.2.0 Structure and function of mitochondria  
 Mitochondria are dynamic organelles that consist of a double membrane and are 
involved in producing large amounts of adenosine triphosphate (ATP), which serves as 
the cell’s energy currency. For this reason, mitochondria are regarded as the 
“powerhouses” of the cell. Each mitochondrion is completely enclosed by an outer 
membrane, while the second inner membrane forms a series of convoluted folds, termed 
cristae. Located within these cristae are the protein complexes that are collectively 
referred to as the electron transport chain (ETC). According to the chemiosmotic theory, 
respiratory complexes within the ETC pump protons across the inner mitochondrial 
membrane (IMM), generating an electrochemical gradient, with the free energy being 
used to synthesize ATP (150).  
 Electron microscopy of skeletal muscle fibres has demonstrated that mitochondria 
form a reticulated network with interconnected mitochondria concentrated under the 
sarcolemma, termed the subsarcolemmal mitochondria (SS) and interspersed amongst the 
myofibrils, designated the intermyofibrillar mitochondria (IMF). Due to the strategic 
arrangement of the SS mitochondria to the peripherally-localized myonuclei, it has been 
postulated that this particular population provides the ATP that is necessary for 
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membrane and nuclear functions. In contrast, it is expected that the IMF mitochondria 
provide the ATP that enables the interaction between actin and myosin, thereby 
facilitating muscle contraction (56). Furthermore, SS and IMF mitochondria have also 
been shown to exhibit different functional, biochemical and compositional properties (3, 
27, 163). These discrepancies may arise due to inherent differences in enzyme and lipid 
compositions or in their capacity for protein synthesis and import.  
1.2.1 Mitophagy 
 As previously mentioned, mitochondria have long been considered as crucial 
organelles, primarily for their role in ATP synthesis. However, mitochondria have also 
established themselves as critical players in other cellular processes including calcium 
homeostasis (34), fuel utilization (88), intracellular signaling (29, 162) and apoptosis 
(131). Due to this wide spectrum of cellular functions, it is evident that mitochondria play 
a pivotal role in maintaining homeostasis within the cell. As a result, the requirement for 
a healthy mitochondrial pool is essential for cell survival.  
 As previously mentioned, autophagy is a highly conserved mechanism that 
involves the degradation of cellular components through the lysosomal machinery (102). 
Remarkably, this process can be highly specific, targeting only particular organelles, such 
as mitochondria. The selective removal of dysfunctional mitochondria by the autophagic 
machinery is known as mitophagy. This process is of particular importance in post-
mitotic tissues like skeletal muscle fibres and neurons since it is the only established 
mechanism for eliminating dysfunctional and harmful organelles. Impairments in this 
system can be observed in several myopathies (49, 114), and is typically characterized by 
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the presence of abnormal mitochondria, oxidative stress, accumulation of 
polyubiquitinated proteins and structural defects to the sarcomere (97).  
  In order to serve as a quality control mechanism, the cell must be equipped with 
specialized proteins that can detect damaged mitochondria and mark them for 
degradation. Specifically, when mitochondria become dysfunctional, a loss of membrane 
potential results (ΔΨ). This loss in ΔΨ results in the stabilization of the serine/threonine 
kinase phosphatase and tensin homolog (PTEN)- induced kinase 1 (PINK1) on the outer 
mitochondrial membrane (OMM) (98). Although PINK1 is constitutively degraded by 
mitochondrial specific enzymes, the loss in ΔΨ prevents its import, allowing for the 
accumulation of PINK1 on the OMM (158). This stabilization of PINK1 facilitates the 
recruitment of the E3-ubiquitin ligase Parkin, which attaches ubiquitin moieties to 
various proteins, targeting them for degradation (98, 109). Among the most prominent 
targets of Parkin-mediated ubiquitination are the mitochondrial fusion proteins mitofusin 
1 and mitofusin 2 (Mfn1 and Mfn2) (164). By promoting proteasomal degradation of 
Mfn1 and – 2, mitochondria become increasingly fragmented, which is necessary for the 
segregation of damaged mitochondrial fragments from the healthy mitochondrial 
network. Concurrently, the ubiquitination of OMM proteins results in the recruitment of 
p62, which functions as an adaptor protein. Since p62 has a ubiquitin binding domain and 
a microtubule-associated protein 1 light chain 3 (LC3) interacting region, it serves as an 
anchor between the tagged mitochondria and LC3-positive phagophores for subsequent 
clearance in the lysosome (63, 119).  
 Evidently, mitophagy serves as an adaptive response to cellular stress by 
eliminating damaged mitochondria in order to preserve mitochondrial and skeletal muscle 
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integrity. Defects in the autophagic machinery result in the accumulation of dysfunctional 
proteins and organelles that can promote myofibre degeneration, or aggravate muscle 
pathologies.   
1.2.2 ROS 
 It is well known that mitochondria are the primary suppliers of ATP within the 
cell. However, through this energy-transducing process, electrons can escape the ETC 
and partially reduce oxygen giving rise to the formation of ROS. As a result, 
mitochondria are often cited as the predominant source of ROS within skeletal muscle 
fibres. Studies investigating mitochondria at the ultrastructural level have identified 
NADH dehydrogenase (complex I) and cytochrome bc1 (complex III) as the major sites 
of superoxide production (107, 134). Interestingly, work conducted by Brand and 
colleagues (133) revealed that the contribution of specific sites to the production of ROS 
was dependent on the substrate being oxidized, indicating that physiological or 
pathological changes in substrate utilization may be an important determinant for free 
radical generation.  
 In the context of exercise, the general consensus is that the increase in ROS 
production that occurs with contractile activity is directly related to the elevated oxygen 
consumption that occurs with increased mitochondrial activity. However, recent reports 
argue that mitochondria may not be the dominant source of ROS during exercise (142). 
Moreover, there is actually an inverse relationship between ROS production and oxygen 
consumption since mitochondria generate more ROS during basal (state 4) respiration 
compared to active (state 3) respiration (8). To lend further perspective, mitochondria are 
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predominantly in state 3 during aerobic contractile activity limiting the generation of 
ROS during contractions (130).  
 Historically, ROS have been viewed as toxic metabolic byproducts and causal 
agents of several pathologies. For instance, ROS have consistently been implicated in the 
development and pathogenesis of insulin resistance and type II diabetes. Cellular models 
of insulin resistance are consistently characterized by elevations in ROS (57) that are 
typically derived from mitochondria (7). Although these findings suggest that increases in 
ROS contribute to insulin resistance, there are data to suggest otherwise. For instance, 
there is evidence indicating that ROS is required for both glucose-induced insulin 
secretion by pancreatic β-cells (86), and enhanced insulin sensitivity (92).  
 It has also been suspected that increases in oxidant production contribute or 
exacerbate the aging process. However, the literature investigating the relationship 
between ROS and lifespan is mixed. In support of a causal role for oxidants, Schriner et 
al. (149) demonstrated that overexpression of catalase in murine mitochondria increased 
longevity and reduced the oxidative damage associated with aging. In contrast, some 
genetic models cast doubt on the idea that “less is better” when it comes to ROS. This has 
been demonstrated in SOD2 transgenic mice, since they do not have an increase in 
lifespan compared with their wild-type counterparts. Furthermore, in some cases these 
mice have displayed growth retardation and decreased fertility (135). Moreover, 
overexpressing a combination of major antioxidant proteins also failed to increase 
lifespan (122). To complicate matters further, mice heterozygous for either mitochondrial 
GPx4 or CLK1 display higher levels of oxidative stress, yet exhibit increases in longevity 
(89, 136).  
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 Currently, a unified model regarding mitochondrially-derived ROS as being a 
beneficial or detrimental agent does not exist. However, there appears to be a small 
window or threshold where ROS can exert beneficial effects. The term hormesis is used 
to describe favourable adaptations in response to nonlethal stressors. Therefore, within 
the confines of this range, cellular stress can promote adaptations that contribute to 
organismal fitness. However, beyond this point, pathologies, senescence or cell death 
may ensue.  
1.3.0 Nrf2-Keap1 Pathway 
1.3.1 Nrf2 and Keap1 domain structure and interaction 
  Nuclear erythroid 2 p45-related factor 2 (Nrf2) belongs to the cap ‘n’ collar 
(CNC) family of transcription factors that share a highly conserved basic region leucine 
zipper (bZip) structure (104). The Nrf2 protein contains 605 amino acids that form seven 
conserved Nrf2-ECH homology (Neh) domains (Fig. 1A). Neh1 contains the CNC- bZip 
motif, which enables Nrf2 to bind to the antioxidant response element (ARE) sequence in 
the promoter of target genes. Furthermore, small Maf proteins heterodimerize with Nrf2 
in this region to facilitate it’s binding to the DNA and increase its transcriptional 
efficiency (64, 67, 72). The N-terminal Neh2 domain is regarded as the negative 
regulatory domain due to its interaction with Kelch-like ECH-associated protein 1 
(Keap1) (66). Additionally, negative regulation of Nrf2 can occur in a Keap1-
independent manner by targeting specific motifs located in the Neh6 domain (25, 99). 
While the Neh 3-5 domains appear to be critical for transactivation by binding to 
different components of the transcriptional apparatus (71, 113), repression of Nrf2 has 
recently been shown to occur through interactions with Neh 7 (176).  
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Figure 1. Domain structures of the transcription factor Nrf2 and its repressor Keap1. (A) 
The proposed positions of the Nrf2 ECH-homology 1-7 domains are indicated. The 
Neh1CNC-bZip domain is responsible for dimerization with the sMaf proteins and 
required for ARE-interaction. Neh2 domain interacts with Keap1. Neh3-5 are important 
for the recruitment of other factors necessary for transcription of target genes. Keap1 
independent negative regulation of Nrf2 can occur through Neh6 and Neh7. (B) Domain 
structure of Keap1. BTB-domain of Keap1 is required to form a Keap1 homodimer. 
Linker region is rich in cysteine residues that can be modified by reactive oxygen species 
(ROS). The Kelch-repeat domain is critical for Nrf2 repression since it interacts with the 
Neh2 domain of Nrf2. 
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The activity of Nrf2 is tightly regulated by Keap1, which was identified through a yeast 
two-hybrid system using the Neh2 domain of Nrf2 as bait (66). Keap1 contains three 
major domains: an N-terminal BTB (broad complex, tramtrack, bric-a-brac) domain, a 
linker region, and a C-terminal Kelch domain (Fig. 1B). Findings from Zipper et al. 
demonstrated that the N-terminal BTB domain is required to form a Keap1 homodimer, 
which is also necessary for the sequestration of Nrf2 (186). Additionally, the Kelch 
domain is also important for the binding of Nrf2 since it interacts with the Neh2 domain 
of Nrf2 (87). Lastly, the cysteine-rich linker region has also been shown to be imperative 
for  Keap1-mediated degradation of Nrf2 (182). 
1.3.2 Redox balance of the cell – Nrf2 activation  
Eukaryotic organisms are constantly challenged by an array of both endogenous 
and exogenous insults that can alter the redox balance of the cell. Therefore, in order to 
combat against these insults they have evolved an elaborate network of cytoprotective 
proteins that confer cellular protection by augmenting their expression in response to 
disturbances in oxidative stress. The transcription factor Nrf2 is regarded as the central 
regulator of the expression of antioxidant and phase II detoxification enzymes since it 
controls their inducible expression (Fig. 2). Abrogation of Nrf2 in mice blunts the 
expression of these enzymes consequently increasing their sensitivity to the toxic effects 
of various drugs (35) and chemical compounds (137). The inability of these mice to 
initiate a response that counteracts the adverse effects of exogenous insults illustrates the 
importance of Nrf2 in maintaining cellular redox homeostasis.  
Although Nrf2 controls the inducible expression of its target genes, its activity is tightly 
regulated by Keap1 (111). Under basal conditions Keap1 binds Nrf2 and targets it for 
ubiquitination and proteasomal degradation via association with the Cul3-based E3 
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ubiquitin ligase complex (31, 76). Due to the negative regulatory system of Keap1, Nrf2 
is rapidly turned over, with a half-life of less than 20 minutes (76). However, increases in 
oxidative stress promote the activation and stabilization of Nrf2. Nrf2 activation is 
thought to involve the modification of the sulfhydryl groups of specific cysteine residues 
found within the linker region of Keap1, which results in a conformational change that 
alters the binding capacity of Keap1 with Nrf2 (77, 182).  This alteration in Keap1 
structure is also thought to inhibit or mask the nuclear exporting signal (NES) within 
Keap1, which is thought to serve as another regulatory element in the sequestration of 
Nrf2 within the cytoplasm (171). This in turn, allows for Nrf2 to dissociate and have its 
nuclear localization signals (NLS) exposed, facilitating its entry into the nucleus. Nrf2 
contains three different NLS (designated NLS1-3) that are essential for its entry and 
function within the nucleus (69, 166). Interestingly, NLS1 is contained within the Neh2 
domain, the domain that is crucial for Nrf2-Keap1 interaction (65, 99). Therefore, under 
non-stressed conditions Keap1’s interaction with Nrf2 at this domain likely conceals this 
sequence, helping to retain Nrf2 within the cytoplasm. Given the central importance of 
Nrf2 in maintaining health (22, 46, 106), the presence of several NLS may provide Nrf2 
with an opportunity to respond to different signals. In any case, it is evident that oxidative 
conditions favour Nrf2 activation in order to mediate an intracellular response that will 
ultimately mitigate damage to the cell and help to bring it back to homeostasis.  
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Figure 2. General scheme for the induction of gene expression through the Keap1-Nrf2 
signaling pathway. Keap1 is a key regulator of Nrf2, serving as a molecular switch for 
the activation or repression of the Nrf2-mediated antioxidant response. A) Under basal 
conditions, the CUL3-Keap1 E3 ubiquitin ligase complex constantly targets Nrf2 for 
ubiquitination and degradation by the 26S proteasome. B) Upon activation, in response to 
increases in reactive oxygen species (ROS) or antioxidant response element inducers, 
distinct cysteine residues on Keap1 are modified, thereby disrupting the association 
between Keap1 and Nrf2. As such, Nrf2 is stabilized and accumulates in the nucleus 
where it heterodimerizes with small Maf proteins and binds to the antioxidant response 
element (ARE) within the promoter region of target genes. Increased expression of 
antioxidants and detoxification enzymes results in an adaptive response that enhances the 
resistance of cells to environmental stresses mediated by electrophiles and ROS. 
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1.3.3 Transcription of antioxidants – Nrf2/ARE regulation 
The upstream regulatory regions of cytoprotective genes contain a consensus 
sequence known as the antioxidant response element (ARE). Through mutational 
analysis, Rushmore et al. were able to identify a core sequence (TGACnnnGC) required 
for phenolic antioxidant-induced gene regulation (139, 140). Since then studies have 
demonstrated that Nrf2 binds to the ARE in order to regulate the ARE-mediated 
antioxidant enzyme gene expression. Moreover, the Nrf2-ARE induction has been shown 
to respond to a number of different stimuli including xenobiotics, antioxidants, metals 
and UV irradiation (48, 51, 80). However, the absence of Nrf2 abolishes this response 
since Nrf2-null mice exhibit a marked reduction in several antioxidant and phase II 
detoxification enzyme genes that are required to protect the cell against increases in 
oxidative stress (64). These results indicate that Nrf2 is imperative for the activation of 
these genes. 
  Importantly, Nrf2 cannot bind to the ARE as a monomer or homodimer. ARE-
mediated transcriptional activation requires Nrf2 to form a heterodimer with small Maf 
proteins. Evidence for this comes from small Maf mutant mice, who demonstrate an 
impaired ability to modulate ARE-dependent genes (72, 105). Additional regulatory 
mechanisms include the recruitment of coactivators that can modify the transcriptional 
activity of Nrf2 by interacting with the Neh4 or Neh5 domain, which are both important 
for Nrf2 transactivation. For instance, p300 or CBP was shown to cooperatively bind 
these sites, augmenting promoter-specific DNA binding of Nrf2 (71, 161). Although a 
number of in vitro and in vivo studies have demonstrated the importance of Nrf2 in 
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upregulating ARE-dependent gene expression, it is clear that the coordinated actions of 
other factors must also be in place. 
 Although Nrf2 activation in response to increases in oxidative stress is critical for 
mounting an appropriate defense response, constitutive activation of Nrf2 can be 
detrimental. For example, Keap1 knockout (KO) mice die postnatally due to 
hyperkeratosis of the esophagus and forestomach (173). While Keap1 certainly serves as 
the central regulatory node against Nrf2 activity, other factors are in place to aid in the 
tight regulation of Nrf2. Under non-stressed conditions BACH1 (BTB and CNC 
homology 1, basic leucine zipper transcription factor 1) forms a heterodimer with small 
Maf proteins on the ARE to repress gene expression (33, 59). However, in the presence 
of oxidative stress BACH1 is released from the ARE and replaced with Nrf2. In a similar 
fashion to Keap1, BACH1’s role as a negative repressor of the ARE is likely to 
contribute to the homeostatic control of ARE-regulated gene expression 
1.3.4 Role of antioxidants 
1.3.4.1 NQO1 
 NADPH quinone oxidoreductase 1 (NQO1) is a cytosolic enzyme that is widely 
distributed in mammalian tissues, though the highest levels are typically observed in the 
heart and liver (185). The principal function of NQO1 is to catalyze the obligatory two-
electron reduction of various quinone compounds and their derivatives by using NADPH 
or NADH as the hydride donor (36). This results in the detoxification of electrophilic 
compounds that could otherwise participate in further redox signaling, generating more 
reactive oxygen intermediates. Furthermore, NQO1 provides an additional layer of 
protection to the cell by scavenging superoxide (155) and ensuring that vitamin E and 
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coenzyme Q (CoQ) remain in their reduced and active forms in order to protect against 
the lipid peroxidation of cell membranes (154, 185).  
Another critical biological function of NQO1 is the stabilization of the tumor 
suppressor protein p53. This protein-protein interaction between NQO1 and p53 works to 
stabilize p53 by preventing its degradation by the 20S proteasome (10). Although the 
exact nature of this interaction has not been fully elucidated, it appears that the catalytic 
activity of NQO1 is not required, suggesting that the oxidation of NADPH is not 
responsible for the stabilization of p53 (9). Similarly, NQO1 has been shown to exert the 
same regulatory actions to PGC-1α. Adamovich et al. (1) revealed that NQO1 binds and 
protects PGC-1α from 20S proteasomal degradation, which plays an important role in 
controlling PGC-1α protein level and activity under basal and physiologically induced 
conditions.   
 1.3.4.2 Heme Oxygenase-1  
 Heme Oxygenase-1 (HO-1) is an antioxidant protein that is rapidly upregulated in 
response to oxidative stress (75). The major enzymatic function of HO-1 is to degrade 
heme resulting in the generation of biliverdin, carbon monoxide (CO) and ferrous iron 
(100). Interestingly, the cytoprotective effects of HO-1 occur in a dual manner. First, HO-
1 is essential for eliminating free heme and preventing it from participating in pro-
oxidant reactions (75). Secondly, biliverdin is rapidly converted to bilirubin which has 
been shown to exhibit antioxidant properties of its own (41, 157). Furthermore, the 
generation of endogenous CO that occurs from the catabolism of free heme has even 
demonstrated protective effects through anti-apoptotic (175), anti-inflammatory (118) 
and mitochondrial quality control functions (81, 83).  
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 HO-1 and CO also work in tandem to confer cytoprotection by promoting 
mitochondrial biogenesis. In cardiac cells, it was found that endogenous CO enhanced 
mitochondrial H2O2 production, resulting in the activation of Nrf2 and nuclear 
translocation of nuclear respiratory factor -1 (NRF-1), a well-known transcription factor 
for mitochondrial biogenesis (145, 172). Nuclear Nrf2 occupied the ARE sites in the 
promoter regions of HO-1, SOD2 and NRF-1, facilitating the transcription of these genes, 
while nuclear accumulation of NRF-1 promoted the activation of downstream genes that 
are required for mitochondrial biogenesis (126). This particular action of the HO-1/CO 
signaling axis appears to couple the pro-survival program of mitochondrial biogenesis 
with the upregulation of cellular antioxidant defenses.  
1.3.4.3 GSH 
 The tripeptide glutathione (GSH) is considered to be the most abundant non-
protein thiol in cells. The synthesis of GSH is ATP-dependent and occurs exclusively in 
the cytoplasm through the actions of γ-glutamylcysteine synthetase and GSH synthase. 
The key functional element of GSH is the reactive thiol-group that is present within its 
cysteine backbone. This allows GSH to participate in oxidation-reduction type reactions 
that facilitate the clearance of electrophiles and other redox species. Although GSH 
serves as a critical reducing agent and antioxidant within the cell, its functions extend 
beyond acting as a redox buffer.  
 In addition to controlling the redox environment within the cell, GSH can also 
modulate the formation of reactive oxygen species (ROS) within the mitochondrion. This 
is accomplished by a post-translational modification known as glutathionylation, which is 
the addition of GSH to the cysteine residue of target proteins. Mailloux et al. (94) 
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demonstrated that the mitochondrial uncoupling proteins 2 and 3 (UCP 2 and UCP3) 
contain reactive cysteines that can be conjugated to GSH, which ultimately controls its 
function. Glutathionylation prevented leaks through UCP2 and- 3 when ROS levels were 
low, however, increases in hydrogen peroxide (H2O2) resulted in the removal of the GSH 
moiety, thereby activating leaks and increasing state 4 respiration. Interestingly, complex 
1 of the electron transport chain (ETC) also serves as a target for GSH conjugation. The 
work of Taylor et al. (165) revealed that mitochondrial complex 1 ROS production is 
linked to the oxidation of the mitochondrial GSH pool. Specific subunits that comprise 
complex 1 were shown to form mixed disulfides with GSH which elicited rapid increases 
in superoxide production. Although it seems counterintuitive that GSH would have a 
mechanism promoting increases in ROS, it may serve as a signaling mechanism that 
informs the cell of the redox environment within the mitochondria. This in turn could 
either signal for the clearance of mitochondria through the autophagic machinery (147), 
or initiate apoptosis (79).  
1.3.5 Other transcription factors for regulating antioxidant capacity  
 In order to prevent against oxidative stress, the cell must respond to increases in 
ROS by upregulating the antioxidant defense system. Since antioxidants are necessary for 
reducing ROS levels, the redox regulation of transcription factors is an important 
component in determining the gene expression profile and cellular response to oxidative 
stress. Although Nrf2 is regarded as the master regulator of antioxidant gene expression, 
other factors including the forkhead box O (FOXO) family of transcription factors and 
PGC-1α have been shown to assists in the redox buffering of the cell by regulating 
antioxidant expression.  
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 The FOXO transcription factors were first linked to stress resistance in C.elegans 
when mutant mice deficient for daf-2, which is orthologous to the mammalian insulin 
receptor, exhibited a phenotype characterized by extended lifespans and resistance to 
oxidative stress (53, 74). It was determined that this phenotype was mediated by the 
transcription factor DAF-16, a FOXO orthologue, since mutations in this gene abolished 
these traits (54). This work suggested that DAF-16, or its mammalian orthologue FOXO, 
may regulate transcriptional targets that protect against oxidative stress. Indeed, 
subsequent research in mammalian tissue found that FOXO regulates a number of 
antioxidants including MnSOD, CuZn-SOD, catalase, Prx3, Prx5, GPx-1 and Trx2 (24, 
78, 96, 110, 117). The fact that FOXO regulates a battery of antioxidants ensures that 
ROS can be buffered in a number of different intracellular compartments. However, this 
assurance is reduced in cells that lack FOXO expression since they exhibit increased 
sensitivity to elevations in ROS, which can ultimately result in apoptosis (112, 115).   
 Although PGC-1α is a potent stimulator of mitochondrial biogenesis, it also 
appears to assist in the coordination of antioxidant expression. Interestingly, increases in 
mitochondrial ROS detoxifying enzymes have been shown to coincide with increases in 
PGC-1α and mitochondrial gene expression (160, 169). Since ROS are a by-product of 
mitochondrial metabolism it seems logical that PGC-1α would balance metabolic 
adaptations and requirements with cytotoxic protection to ensure mitochondrial and 
cellular integrity. In support of this, PGC-1α null mice display a blunted induction of the 
ROS defense system, predisposing these mice to oxidative injury and neuronal lesions 
(159). Furthermore, it has been demonstrated that PGC-1α is indispensable during 
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differentiation since its absence was characterized by increased ROS production, 
reduction in mitochondrial mass and function and muscle degeneration (12).  
 Despite the fact that ROS can serve as important signaling molecules, 
uncontrolled regulation is detrimental to the cell. Therefore, it is imperative that there are 
systems in place that can counteract and tightly regulate their abundance. As such, the 
functions of Nrf2, FOXO and PGC-1α serve to coordinate a line of defense against any 
outbursts in ROS. Evidently, impairments within any one of these systems renders the 
cell more susceptible to the deleterious effects of ROS.  
1.4.0 Research Objectives  
Therefore, based on the review of literature, the objectives of my thesis, using Nrf2 KO 
mice were:  
1. To determine if Nrf2 is activated in skeletal muscle in response to exercise; 
2. To investigate the tolerance and endurance capacity of Nrf2 KO mice by 
subjecting them to an exhaustive exercise test;  
3. To examine the effect of Nrf2 on exercise-induced mitochondrial biogenesis;  
4. To evaluate the effect of Nrf2 on mitochondrial respiration and ROS production; 
5. To assess the role of Nrf2 in determining the contractile properties of skeletal 
muscle 
6. To determine if age exacerbates the loss of Nrf2 on muscle performance or 
mitochondrial content 
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1.4.1 Hypothesis 
We hypothesized that: 
1. Nrf2 would be activated in skeletal muscle in response to exercise;  
2. Nrf2 KO mice would have a lower endurance capacity relative to their WT 
counterparts;  
3. The absence of Nrf2 would attenuate exercise-induced mitochondrial biogenesis; 
4. Abrogation of Nrf2 would impair mitochondrial respiration and result in greater 
ROS production; 
5. Force production and endurance would be impaired in the KO animals in situ; 
6. Aging would exacerbate the loss of Nrf2.  
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Abstract 
Nuclear factor erythroid 2–related factor 2 (Nrf2) is a transcription factor that 
confers cellular protection by upregulating antioxidant enzymes in response to oxidative 
stress. However, Nrf2 function within skeletal muscle remains to be elucidated. Thus, we 
examined the role of Nrf2 in mediating changes in skeletal muscle phenotype using Nrf2 
wild-type (WT) and knockout (KO) mice at 3 and 12 months of age. Basally, Nrf2 did 
not impact muscle mitochondrial content in young and older animals. In IMF 
mitochondria, lack of Nrf2 resulted in a 40% reduction in state 4 respiration, which 
coincided with a 68% increase in ROS production. Nrf2 abrogation impaired in situ 
muscle performance, characterized by a 48% greater rate of fatigue, and a 35% decrease 
in force production within the first 5 minutes of stimulation. Acute treadmill exercise 
resulted in a 1.5-fold increase in Nrf2 activation, via enhanced DNA binding in WT 
animals. In response to training COX activity increased by 20% in the WT animals, 
however this response was attenuated in the KO mice. Despite this, exercise training was 
capable of normalizing respiration, ROS production and muscle endurance performance 
to that found in WT levels. Interestingly, antioxidant enzyme expression did not differ 
between genotypes regardless of training status or age, indicating alternative regulatory 
mechanisms. Our results suggest that Nrf2-mediated transcriptional activity is increased 
by acute exercise and that Nrf2 is required for normal exercise-induced adaptations in 
mitochondrial content, but that improvements in mitochondrial function resulting from 
exercise appear to be Nrf2-independent. 
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Introduction 
 Eukaryotic organisms are constantly challenged by an array of both endogenous 
and exogenous insults that can alter the redox balance of the cell. Therefore, in order to 
combat these insults, cells have evolved an elaborate network of proteins that confer 
cellular protection by augmenting their expression in response to disturbances in 
oxidative stress. Nuclear factor erythroid 2–related factor 2 (Nrf2) is a transcription factor 
that has a pivotal role in mediating this intracellular antioxidant response since it 
upregulates the expression of numerous antioxidant and phase II detoxification enzymes, 
in response to increases in oxidative stress (30). Mice deficient for Nrf2 exhibit a marked 
reduction in the expression of these enzymes, consequently increasing their sensitivity to 
the toxic effects of various drugs (12) and chemical compounds (32). The inability of 
these mice to initiate a response that counteracts the adverse effects of oxidative stress 
illustrates the importance of Nrf2 in maintaining cellular redox homeostasis.  
 Under quiescent conditions, the Nrf2 signaling pathway is negatively regulated by 
Kelch-like ECH associating protein 1 (Keap1). Keap1 constitutively targets Nrf2 for 
ubiquitin conjugation and subsequent proteasome degradation in the cytoplasm by acting 
as a substrate adaptor for the Cul3-based E3 ubiquitin ligase complex (10, 19). Due to the 
negative regulatory system of Keap1, Nrf2 is rapidly turned over, with a half-life of less 
than 20 minutes  (19). However, increases in oxidative stress promote the activation and 
stabilization of Nrf2. Nrf2 activation is thought to involve the modification of the 
sulfhydryl groups of specific cysteine residues found within the linker region of Keap1, 
which results in a conformational change that alters the binding capacity of Keap1 with 
Nrf2 (20, 43). In turn, this promotes the translocation of Nrf2 to the nucleus where it can 
54 
 
interact and form heterodimers with small Maf proteins (16, 17), recruit transcriptional 
coactivators (38, 40) to help remodel chromatin structure, and bind to the antioxidant 
response element (ARE) found within the promoter region of target genes (30).  The fact 
that Keap1 contains distinct cysteine residues (43) that can be targeted and modified by 
electrophiles, reactive oxygen species (ROS) or antioxidant response element-inducers, 
suggests that the Keap1-Nrf2 interaction functions as a sensor of the redox state of the 
cell.  
 While it is well-established that Nrf2 is important for antioxidant expression, 
emerging evidence also suggests that Nrf2 signaling protects the structure and function of 
skeletal muscle, in part, through the preservation of redox homeostasis. For instance, 
Safdar et al. (34) reported a significant decrease in nuclear Nrf2 expression in elderly 
humans leading a sedentary lifestyle, while recreationally active individuals exhibited 
improved Nrf2 function. Disruption of Nrf2 has also been shown to induce oxidative 
stress resulting in greater ubiquitination, lipid peroxidation and pro-apoptotic signals in 
skeletal muscle of aged Nrf2 KO mice (25). Further, aged Nrf2 KO mice also 
demonstrate impaired muscle regeneration following acute endurance exercise stress due 
to a decrease in Pax7 and MyoD expression (29). Interestingly, Nrf2 has also been 
implicated in regulating mitochondrial content (31) and function (15, 18) in some cell 
types. The work conducted by Piantadosi et al. (31) revealed that nuclear respiratory 
factor 1 (NRF-1) contains multiple ARE’s within its promoter that become occupied by 
Nrf2 upon induction by ROS. Exhaustive exercise has also been shown to be a particular 
stressor capable of inducing Nrf2 activation, nuclear accumulation and ARE-binding 
within cardiomyocytes (28). However, the role of Nrf2 in mediating changes in 
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mitochondrial content and function in skeletal muscle remains to be elucidated. 
Therefore, the purpose of our study was to examine the role of Nrf2 within skeletal 
muscle, its impact on mitochondrial content, and its relationship to exercise performance 
in young and middle-aged mice. Furthermore, we also subjected both Nrf2 wild-type 
(WT) and knockout (KO) animals to a six-week training protocol to determine if Nrf2 
was required for mitochondrial biogenesis in skeletal muscle. 
Methods 
Animals. Nrf2 KO and heterozygous mice (maintained on a C57BL/6J background) were 
obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). Animals were bred in 
accordance with the guidelines of the York University Animal Care Committee. Progeny 
were genotyped by obtaining ear clippings, which were subsequently used for crude 
DNA extraction. DNA extracts were incubated with Jumpstart RED-Taq DNA 
polymerase (Sigma; St. Louis, Missouri, USA), as well as forward and reverse primers 
specific to the wildtype or mutant nucleotide sequences, and amplified using polymerase 
chain reaction (PCR). The reaction products were separated on a 1.0% agarose gel, and 
visualized with the use of ethidium bromide. Nrf2 WT and KO animals were used at 3 
and 12 months of age.  
Voluntary wheel running. At 3 months of age, Nrf2 WT and KO mice were aged 
matched and assigned to a control or running group. The mice were housed individually, 
allowed access to food and water ad libitum, and kept on a 12:12-h light-dark cycle. 
Runners had access to a freely rotating wheel, while the revolutions were recorded by a 
magnetic counter. The number of revolutions was recorded every 24 hours and converted 
into distance (kilometres) per day. The duration of the training protocol was ~6-8 weeks. 
56 
 
Following the training protocol mice were subjected to an endurance exercise capacity 
test and in situ stimulation for further performance analysis.  
Acute In situ muscle stimulation. The stimulation protocol was performed as described 
previously (36). Briefly, the sciatic nerve of the gastrocnemius muscle from one leg was 
stimulated at 0.25 tetanic contractions per second (TPS), 0.5 TPS and 1 TPS for 3 
minutes each. 
These intensities were sufficient to induce moderate and more severe muscle fatigue, 
respectively. Following the in situ stimulation protocol, the stimulated muscle was 
excised, quickly frozen and weighed.  
COX activity. COX enzyme activity was measured as previously described (41) by 
determining the maximal rate of oxidation of fully reduced cytochrome c, evaluated as a 
change in absorbance at 550 nm using a microplate reader (Bio-Tek synergy HT, BioTek 
Instruments, Inc., Winooski, VT, USA).  
Immunoblotting. Whole muscle protein extracts from the gastrocnemius muscle were 
separated using SDS-PAGE and subsequently transferred onto a nitrocellulose 
membrane. Following the transfer, the membranes were blocked for 1 hour with a 
solution of 5% skim milk in 1X TBST (Tris-buffered saline-Tween 20: 25 mM Tris·HCl, 
pH 7.5, 1 mM NaCl, and 0.1% Tween 20). Membranes were then incubated overnight at 
4°C with antibody directed against HO-1 (Abcam, ab13248), NQO1 (Abcam, ab34173), 
G6PD (Cell Signaling, 8866) and GPx1 (Abcam, ab22604). After three 5 minute washes 
with TBST, blots were incubated at room temperature for 1 hour with the appropriate 
secondary antibody coupled with horseradish peroxidase. Antibody-bound protein was 
revealed using the enhanced chemiluminescence method. Quantification was performed 
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with Image J Software (NIH, Bethesda, MD, USA), and values were normalized to the 
appropriate loading controls.  
Mitochondrial isolation. The tibialis anterior, gastrocnemius, quadriceps and triceps 
muscles from both sides of the animal were minced, homogenized and subjected to 
differential centrifugation to isolate SS and IMF mitochondrial fractions, as described 
previously (8). Mitochondria were suspended in resuspension buffer (100 mM KCl, 10 
mM MOPS, and 0.2% BSA). Following the isolation procedure, SS and IMF were used 
to assess mitochondrial respiration and reactive oxygen species (ROS) production.  
Mitochondrial Respiration. Fifty microliters of isolated mitochondrial samples were 
incubated with 250 μl of VO2 buffer (in mM: 250 sucrose, 50 KCl, 25 Tris, and 10 
K2HPO4, pH 7.4) in a Clark oxygen electrode respiratory chamber (Strathkelvin 
Instruments, North Lanarkshire, Scotland) with continuous stirring at 30°C. 
Mitochondrial oxygen consumption was measured in the presence of exogenously added 
10 mM glutamate to assess state 4 respiration followed by 0.44 mM ADP to elicit state 3 
respiration. Finally, NADH was added during state 3 measurements to evaluate the 
integrity of the inner mitochondrial membrane. 
Mitochondrial ROS production. SS and IMF mitochondria (75μg) were incubated with 
50 μM dichlorodihydrofluorescein diacetate (H2DCF-DA) and VO2 buffer at 37°C for 30 
min in a white polystyrene 96-well plate. The fluorescence emission (between 485 and 
528 nm) is directly proportional to ROS production and was measured with a Synergy 
HT microplate reader. ROS production was assessed under both state 4 and state 3 
respiration. 
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Nrf2 activation assay. Nrf2 activation and antioxidant response element binding efficacy 
under both basal and acute exercise stress conditions were evaluated in WT and KO mice 
using nuclear extracts obtained from the TA muscle, using a Trans AM Nrf2 kit (50296, 
Active Motif, Carlsbad, CA). A 10μg aliquot of nuclear protein was incubated with 
immobilized oligonucleotides containing the ARE consensus binding site 
(5′GTCACAGTACTCAGCAGAATCTG-3’). Active Nrf2 that bound to the oligo was 
detected with the Nrf2 primary antibody and subsequent HRP-conjugated secondary 
antibody. Specific activity of Nrf2 in the nuclear extracts was determined using a plate 
reader at 450 nm, and absorbance was expressed as the direct activity of Nrf2.  
Endurance exercise capacity test. Nrf2 WT and KO mice were acclimated to the 
treadmill for two days prior to the test. On the exercise testing day, the mice ran on the 
treadmill with a fixed slope of 10%. Mice ran for 5m/min for 5 minutes followed by 
10m/min for 10 minutes, 15m/min for 15 minutes and 20m/min for 20 minutes. The 
speed was then increased by 2m/min every 2 minutes until exhaustion was achieved. 
Exhaustion was defined as the inability of the animal to run on the treadmill for 10 
seconds despite prodding. 
Nuclear and cytosolic fractionation. Immediately following the endurance exercise 
capacity test, the TA muscle was immediately removed and placed into ice-cold 
phosphate buffered saline with protease inhibitors. Nuclear and cytosolic fractionation 
was conducted using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit 
(Thermo Fisher Scientific) according to the manufacturer’s protocol.  
 Statistical Analysis. Data were analyzed using Graphpad 6.0 software. Values are 
reported as means ± SEM. A Student’s T-Test was used to analyze the Nrf2 activation 
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assay and comparisons between slopes during the initial two-minutes of in situ 
stimulation. State 4 and state 3 respiration and ROS were analyzed using an ANOVA. All 
other data were analyzed with a 2-Way ANOVA unless otherwise indicated. Significance 
levels were set at P<0.05 using a Bonferonni post-hoc test.    
Results 
Response of Nrf2KO mice to voluntary exercise. To evaluate the effect of Nrf2 on 
exercise-induced adaptations, both WT and KO mice were subjected to six-weeks of 
voluntary running wheel exercise training. Throughout the six week period, the WT and 
KO mice exhibited no differences in running performance, as both genotypes averaged 
~11 km/day (Fig. 1A). Body mass and gastrocnemius weight were evaluated in the WT 
and KO mice at 3 and 12 months of age, respectively, to determine the effect of training, 
or age. There was no effect of training or genotype on body mass (Fig. 1B) or 
gastrocnemius mass (Fig. 1C). Although the WT and KO mice at 12 months of age did 
not differ from each other in body mass, the older animals had a ~38% greater body mass 
relative to their younger counterparts, and they displayed a ~19% reduction in 
gastrocnemius mass. These results indicate that the Nrf2 KO mice do not differ from their 
WT counterparts in their voluntary running performance or phenotypic traits at 3 and 12 
months of age. 
Endurance performance of Nrf2 KO mice following 6 weeks of wheel running. 
Following the six-weeks of voluntary wheel running we assessed the exercise tolerance 
of WT and KO mice by subjecting them to an endurance exercise capacity test. Untrained 
Nrf2 KO mice exhibited a similar running distance and time to exhaustion to their WT 
counterparts (Figs. 2A, 2B). In addition, both genotypes adapted equally well to training, 
with 109% and 134% increases in running distance in the KO and WT mice, respectively. 
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As expected, the WT and KO older animals displayed attenuated endurance capacities, 
characterized by 28% and 17% lower distances and times to exhaustion, relative to the 
young untrained mice. Lactate levels were elevated from approximately 2 mM at rest, to 
7-11 mM following exercise. There were no effects of age, training status or genotype on 
lactate levels (Fig. 2C). 
In situ stimulation and force production. To further evaluate the role of Nrf2 in force 
generation and fatigability in isolated muscle, we stimulated the gastrocnemius-plantaris-
soleus muscle group in situ in anesthetized mice at 0.25, 0.50 and 1 TPS (Fig. 3A). 
Maximum tetanic force, time to peak tension and half relaxation were similar in all 
groups (Table 1). However, within the first two minutes of stimulation, the KO untrained 
animals demonstrated a 48% greater rate of fatigue (p<0.05) relative to the WT untrained 
animals (Fig. 3B). Indeed, the untrained KO mice demonstrated significantly increased 
rates of fatigue as determined by lower force generation at both the 5 and 9 minute time 
points (Figs. 3C, 3D). Endurance training abolished this defect and normalized the 
fatigue in the KO animals to that found in WT untrained animals. Collectively, these 
results suggest that Nrf2 is important for the maintenance of fatigue resistance in skeletal 
muscle.  
Adaptability of Nrf2 KO mice following 6 weeks of wheel running. To investigate 
whether differences in muscle fatigability could be attributed to changes in mitochondrial 
content, and to evaluate whether Nrf2 was required for mitochondrial adaptations to 
exercise, we measured COX activity, a well-established biochemical indicator of 
mitochondrial volume. There was no observed difference in COX activity between the 
WT and KO animals at either 3 or 12 months of age (Fig. 4A). While training enhanced 
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COX activity by 20% in the WT animals, this increase was only 10% in the KO mice, 
suggesting that Nrf2 could be required for exercise-induced mitochondrial adaptations. 
To verify this further, we used immunoblotting to measure alternative mitochondrial 
markers (Fig. 4B). Thus, we also probed for COXI (Figs. 4B, 4C) and COXIV (Figs. 4B, 
4D) in whole muscle samples as an ancillary measure of mitochondrial content, however, 
no effect of genotype or training was observed. However, a significant increase in TFAM 
expression in the trained animals relative to their untrained counterparts was noted in 
both WT and KO animals (Fig. 4E). Surprisingly, TFAM expression was significantly 
higher overall in KO animals. Thus, Nrf2 is involved in exercise-induced mitochondrial 
biogenesis in a protein-specific manner. This involvement would imply that Nrf2 could 
be activated during exercise. To verify this in response to an exhaustive bout of exercise, 
we utilized nuclear extracts from WT tibialis anterior muscle at 3 months of age in an 
ARE-oligonucleotide-based transactivation assay. Following the exhaustive bout of 
exercise, skeletal muscle Nrf2 activity was significantly increased (1.5-fold) compared to 
the sedentary WT mice (Fig. 4F). These results suggest that exercise is capable of 
increasing Nrf2-DNA binding and transcriptional activity in skeletal muscle. 
Respiration and ROS production. To determine if the absence of Nrf2 has an effect on 
respiration or ROS production, we isolated both the subsarcolemmal (SS) and 
intermyofibrillar (IMF) mitochondria. Lack of Nrf2 did not affect either state 4 or state 3 
respiration rates in SS mitochondria (Fig. 5A). However, state 4 respiration in IMF 
mitochondria was reduced by 40% in the untrained KO animals relative to WT controls 
(Fig. 5B). Six weeks of voluntary wheel running completely rescued this effect, and 
augmented state 3 respiration rates by 33% (p<0.05). In addition, although no differences 
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were observed in the SS mitochondria (Fig. 5C), ROS production in IMF mitochondria 
was particularly affected by the loss of Nrf2. Under state 4 conditions we observed a 68% 
(p<0.05) increase in ROS in the KO untrained animals compared to the WT animals (Fig. 
5D). Training was sufficient to rescue this response in the KO animals. Taken together, 
these results indicate that the SS and IMF mitochondria respond differently to the loss of 
Nrf2. In particular, IMF mitochondria exhibit a greater dependence on Nrf2-driven gene 
expression for the maintenance of basal respiration rates.  
Compositional differences in isolated IMF mitochondria following training. To 
determine if compositional differences account for some of the functional discrepancies 
between the WT and KO IMF mitochondria we measured different electron transport 
chain (ETC) subunits as well as TFAM. Interestingly, we did not observe any difference 
in either COXI or COXIV protein expression (Fig. 6A). However, we did observe a main 
effect of training regarding UQCRC2 (Fig. 6B) and TFAM expression (Fig. 6C). 
Antioxidant enzyme expression. To assess whether Nrf2-deficiency influenced the levels 
of key antioxidant enzymes, we examined NQO1, HO-1, G6PD and GPx1 protein levels 
in muscle since these are well-established downstream targets of Nrf2 identified in other 
tissues. Abrogation of Nrf2 resulted in significant reductions in NQO1 protein expression 
(Fig. 7A). Training could not rescue this effect in the KO animals, indicating that NQO1 
expression is heavily reliant on the presence of Nrf2 under both basal and stressful 
conditions. Curiously, despite the reductions observed in NQO1, we did not find any 
differences in the level of other Nrf2 targets in muscle between WT and KO animals 
(Figs 7B, 7C, 7D).  
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Differences in antioxidant enzyme expression with age. To investigate whether the lack 
of effect of Nrf2 KO on antioxidant enzyme expression was influenced by age, we 
compared young and older animals.  Interestingly, we observed a 45% increase (p<0.05) 
in NQO1 expression in the older WT animals compared to the young (Fig. 8A). 
However, significant reductions in NQO1 continued to be observed in the older KO 
animals. Conversely, HO-1 expression was increased 62% (p<0.05) in the older KO 
animals relative to the WT young mice (Fig. 8B). Age and genotype did not influence the 
expression of either G6PD or GPx1 (Figs 8C, 8D).  
Discussion  
Exercise is a potent stimulus and metabolic stressor that is capable of provoking 
adaptations in skeletal muscle which allow it to meet repeated increases in metabolic 
demand. One of the most dramatic phenotypic adaptations that occurs in response to 
exercise training is the increase in mitochondrial content and ultrastructure, a process 
commonly referred to as mitochondrial biogenesis. Although mitochondrial regulation 
depends on the interplay between transcription factors such as NRF-1/2, PPARα, ERRα 
and Sp1, in addition to members of the PGC-1 family of regulated coactivators (PGC-1α 
and PGC-1β) (37), the role of Nrf2 in regulating mitochondrial content and function 
within skeletal muscle has not been established. Through a wealth of experimental 
evidence, the prevailing view of Nrf2 is that it sits at the crux of cellular defense 
mechanisms that are important for adaptive and survival responses under conditions of 
stress (7, 11, 30, 42). However, it is becoming apparent that Nrf2 has a much broader 
function since it has emerging roles in metabolism, bioenergetics, skeletal muscle 
integrity as well as mitochondrial content and function (15, 18, 25, 26, 29, 31, 34, 39, 
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42). For instance, genetic deletion of Nrf2 in mouse liver leads to a reduction in 
mitochondrial content (44) . In embryonic fibroblast, loss of Nrf2 was shown to impair 
mitochondrial respiration, resulting in a greater reliance on glycolysis for ATP generation 
(15). It has also been demonstrated in cultured cells that Nrf2 knockout affects the 
efficiency of mitochondrial fatty acid oxidation (24) and increases the susceptibility of 
mitochondria to the permeability transition (39). Our data also suggest that Nrf2 is 
required for basal mitochondrial function since the ablation of Nrf2 impaired state 4 
respiration rates of IMF mitochondria in muscle from KO animals by 40%, and ROS 
emission in the IMF mitochondria was significantly elevated in the null animals during 
state 4 conditions. These results are in accordance with those obtained in MEFs (15) and 
cortical neurons (21). However, abrogation of Nrf2 did not result in an increase in ROS 
production within the myocardium (28) suggesting that there may be tissue-specific 
differences in the dependence of mitochondrial function of Nrf2. Although we did not 
observe any compositional differences in the IMF mitochondria of WT and KO animals 
using a limited number of organelle markers, it is possible that changes in mitochondrial 
respiration and ROS production could be due to differences in uncoupling protein 3 
(UCP3) expression. Anedda et al. (5) identified an ARE within the UCP3 promoter that 
bound Nrf2 after exposure to H2O2. Furthermore, siRNA against Nrf2 prevented the H2O2 
– induced UCP3 expression, which culminated in an increase in oxidative stress and cell 
death. Indeed, we have previously shown that UCP3 content is 1.3-fold greater in IMF 
compared with SS mitochondria, which may partially explain the dissimilar effects of 
Nrf2 abrogation on mitochondrial function between the two subfractions (22).  
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Given the impact of Nrf2 on mitochondrial function, we sought to investigate the 
exercise tolerance of the KO animals by subjecting them to an exhaustive run at both 3 
and 12 months of age. Interestingly, the untrained KO mice displayed comparable 
distances and times to exhaustion, as well as similar lactate production relative to their 
WT counterparts. While, the reductions in endurance capacity evident in the 12 month 
old animals are consistent with the notion that older animals typically display lower 
endurance and greater rates of fatigue (23), the absence of Nrf2 did not hinder running 
performance even at an older age. The lack of any difference in endurance capacity 
between the young untrained WT and KO animals is likely because active (state 3) 
respiration was comparable between the two genotypes. Given that mitochondrial 
respiration during aerobic contractile activity likely reflects rates similar to state 3 
respiration in vitro, this suggests that the KO mice would not have experienced a 
functional deficit in ATP provision sufficient enough to inhibit their running capacity. 
Interestingly, this did not translate into identical muscle performance when we 
investigated the contractile properties of skeletal muscle of Nrf2 WT and KO mice in 
situ. Our findings demonstrated that while there was no difference in the maximal 
strength of the muscle, the endurance capacity of Nrf2 KO skeletal muscle was reduced. 
This difference between whole body and isolated muscle performance characteristics may 
be due to behavioural differences between WT and KO mice.  Muramatsu et al. (27) have 
argued that dopaminergic and serotonergic neurotransmission is enhanced in the KO 
animals, which increases their ability to resist stress. Therefore, the use of the in situ 
muscle preparation was advantageous in eliminating whole body exercise effects, 
ultimately allowing us to delineate any inherent differences in muscle contractile activity. 
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The greater rate of fatigue observed in the untrained KO animals may be partially 
attributed to high levels of ROS exposure. Indeed, we did observe a profound increase in 
mitochondrially-derived ROS in the KO animals. Additionally, Kovac et al. (21) found 
that NADPH oxidase 2 (NOX2) is dramatically upregulated under conditions of Nrf2-
deficiency. Recently, it has been argued that the NOX enzymes are the major ROS 
generating source in contracting skeletal muscle (35). We speculate that an increase in 
ROS generation, partly as a result of mitochondrial dysfunction, may have promoted 
alterations in myofilament structure and function (6, 9, 14), diminished myofilament 
calcium sensitivity (3, 4), or influenced cross-bridge kinetics (4), leading to a greater rate 
of fatigue.  
While evidence pertaining to the importance of Nrf2 for mitochondrial function is 
beginning to accumulate, no research has been devoted to understanding the relationship 
between Nrf2 in muscle during stressful conditions. Research conducted by Piantadosi et 
al. (31) revealed that in response to increases in ROS, Nrf2 translocates to the nucleus 
and occupies several ARE’s within the NRF-1 promoter. These findings, along with our 
observation that exercise can activate Nrf2 in skeletal muscle, suggest that Nrf2 may 
participate in the signaling events that culminate in the expansion of the mitochondrial 
reticulum with exercise training. The exercise-induced activation of Nrf2 is likely 
mediated by an increase in ROS production, since previous reports have shown that ROS 
can be a primary trigger promoting the dissociation of Nrf2 from Keap1, resulting in an 
increase in nuclear translocation and transcription of putative targets (19, 20, 33, 43). 
 To explicitly explore the relationship between Nrf2 and mitochondrial content we 
subjected WT and KO animals to six weeks of voluntary wheel running. Basally, we did 
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not observe any difference in COX activity between the two genotypes at either 3 or 12 
months of age. However, significant training-induced increases in COX activity were 
only observed in the WT animals, suggesting that Nrf2 is required for exercise-induced 
increases in the activity of this terminal enzyme of the electron transport chain. However, 
Nrf2 did not appear to be required for the training-induced increases in TFAM or 
UQCRC2. Thus, Nrf2 appears to be required for the exercise-induced increases in only a 
subset of mitochondrial proteins. Interestingly, despite the blunted change in COX 
activity, training augmented the respiratory deficit which was evident in the absence of 
Nrf2, ultimately restoring it to WT levels. This suggests that Nrf2 is required for the 
normal, stoichiometric protein adaptations in response to training, but is not required for 
the associated improvements in organelle function. Similar results have been reported by 
our laboratory using PGC-1α KO animals, whereby training elicited improvements in 
respiration back to normal levels despite, the absence of PGC-1α (2). Therefore, chronic 
exercise training likely stimulates alternative regulatory proteins that are capable of 
augmenting respiration to compensate for the blunted increase in mitochondrial content 
observed with the absence of Nrf2. 
One of our most striking findings was the marked reduction in NQO1 expression 
in the Nrf2 null animals, a result suggesting that the primary regulation of NQO1 is Nrf2-
dependent. NQO1 is an oxidoreductase which is typically located within the cytoplasm. 
These drastic reductions in NQO1 could predispose the KO animals to metabolic 
abnormalities, since NQO1-deficient mice exhibit higher levels of hepatic triglycerides 
and are insulin resistant (13). In addition, low NQO1 expression can have  ramifications 
for the stability of PGC-1α, since NQO1 appears to be critical for the protection and 
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stabilization of both basal and physiologically-induced PGC-1α protein (1). Interestingly, 
its low expression in Nrf2 KO animals was not rescued by endurance training, suggesting 
that improvements in metabolic conditions associated with NQO1 deficiency would 
likely benefit more from pharmacological interventions.  
In summary, our results suggest that Nrf2-mediated transcriptional activity is 
increased by acute exercise, and that Nrf2 is required for normal, exercise-induced 
adaptations in mitochondrial proteins. Chronic exercise rescued the deficits in respiration 
in an Nrf2-independent manner. We speculate that this effect of exercise may be due to a 
compensatory upregulation of alternative regulatory proteins which impact the expression 
of functional mitochondrial components in the absence of Nrf2, highlighting the ability of 
exercise training to activate a broad array of signaling pathways leading to physiological 
adaptations.  
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Figure Legends 
Table 1. Contractile properties of Nrf2 WT and KO skeletal muscle. 
Figure 1: Voluntary wheel running and body and gastrocnemius weight in Nrf2 WT 
and KO mice. (A) Weekly average wheel running distance accumulated by 3 month old 
Nrf2 wild-type (WT) and knockout (KO) mice over a period of 6 weeks (n=9-10); 
UT=untrained, T=trained. (B) Body and (C) gastrocnemius weight of Nrf2 WT and KO 
mice following the 6 week training period (n=6-10). Data are means ± SEM. *P<0.05; 2-
way ANOVA produced a main effect of age.  
Figure 2: Endurance exercise capacity test. Following the six weeks of voluntary 
wheel running, the running performance of untrained, trained and aged mice were 
compared by subjecting them to an exhaustive bout of exercise. Running performance 
was measured by recording both the (A) distance (n=6-9) and (B) time (n=6-9) to 
exhaustion. *P<0.05 T vs. UT; ¶<0.05 main effect of age, 2-way ANOVA. (C) Lactate 
production was also measured before and after exercise. *P<0.05, 2-way ANOVA 
produced a main effect of exercise. 
Figure 3: Muscle performance in response to acute in situ stimulation. (A) The 
gastrocnemius muscle of WT UT, WT T, KO UT and KO T mice was stimulated at 0.25, 
0.50 and 1 tetanic contraction per second (TPS) with force production being used as an 
index of muscle fatigue (n=8-10). (B) Graphical representation depicting the linear 
regression of the WT UT and KO UT fatigue rate within the first two minutes of 
stimulation. *P<0.05 WT UT vs. KO UT, Student’s t-test. (C) Force production at 5 
minutes of stimulation. *P<0.05 WT UT vs. KO UT; ¶<0.05 KO UT vs. KO T, ANOVA. 
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(D) Force production at end of stimulation. ¶<0.05 KO UT vs. KO T, ANOVA. Data are 
means ± SEM.   
Figure 4: Adaptations to training in the Nrf2 WT and KO animals. (A) COX activity 
(n=6-7) of the gastrocnemius muscle in response to voluntary wheel running or age. 
**P<0.01 T vs. UT, 2-way ANOVA. (B) Western blots of COX1, COXIV and TFAM 
from whole muscle samples in Nrf2 WT and KO mice following six weeks of voluntary 
wheel running. Graphical representation of (C) COXI (n=3) (D) COXIV (n=7-9) and (E) 
TFAM (n=7-9). *P<0.05 vs. UT, ¶<0.05 main effect of genotype, 2-way ANOVA. Data 
are means ± SEM.  (F) ARE-based transactivation assay (n=7) to determine if exercise 
can induce Nrf2 activation; bars represent fold-change in acute exercise group relative to 
sedentary mice. *P<0.05, Student’s t-test. Data are means ± SEM.  
Figure 5: Respiration and ROS production in isolated mitochondria from Nrf2 WT 
and KO animals. Oxygen consumption in isolated (A) SS (n=6-8) and (B) IMF 
mitochondria (n=10) during state 4 and state 3 respiration. *P<0.05 KO UT vs. WT UT; 
¶<0.05 T vs. UT, ANOVA. Reactive oxygen species (ROS) production in the (C) SS and 
(D) IMF mitochondria during state 4 and state 3 respiration. *P<0.05 KO UT vs. WT 
UT; ¶ P<0.05 KO T vs. KO UT. Data are means ± SEM.   
Figure 6: Compositional differences in isolated IMF mitochondria from trained and 
untrained mice. Western blots depicting COXI (n=6), COXIV (n=6), TFAM (n=6), 
UQCRC2 (n=6) protein expression in isolated IMF mitochondria. Graphical 
representation of (A) UQCRC2 and (B) TFAM. *P<0.05 main effect of training, 2-way 
ANOVA. Data are means ± SEM.  
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Figure 7: Antioxidant enzyme expression in skeletal muscle of trained and 
untrained mice. Western blots depicting (A) NQO1 (n=6), (B) HO-1 (n=7), (C) G6PD 
(n=9) and (D) GPx1 (n=9) protein expression in WT and KO mice in both untrained and 
trained conditions. *P<0.05; 2-way ANOVA produced a main effect of genotype. Data 
are means ± SEM.   
Figure 8: Antioxidant enzyme expression in young and middle-aged WT and KO 
mice. Western blots depicting (A) NQO1 (n=7) (B) HO-1 (n=5-7) (C) G6PD (n=5-7) and 
(D) GPx1 (6-7) protein expression in young and middle-aged WT and KO mice. *P<0.05 
versus WT Y, ANOVA; ¶ P<0.05 KO A vs. WT Y/A, ANOVA. Data are means ± SEM.  
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Table 1 
Condition GW 
(mg) 
GW(mg)/BW(g) TW/GW 
(mN/mg) 
TET/GW 
(mN/mg) 
TPT 
(msec) 
½ RT 
(msec) 
WT UT 173.5 ± 
5.45 
5.87±0.17 1.83          
± 0.35 
6.72         
± 0.54 
21.36 ± 
1.16        
35.36 ± 
1.76 
WT T 162.4 ± 
8.53 
5.69±0.16 2.39         
± 0.27 
6.56          
± 0.59 
22.17 ± 
2.01 
34 ± 
4.12 
KO UT 169.40 ± 
5.92 
5.71 ± 0.14 2.01         
± 0.14 
5.43          
± 0.57 
18.67 ± 
1.91 
32.4 ± 
2.29 
KO T 176.89 ± 
10.93 
5.62 ± 22 2.25          
± 0.21 
6.91          
± 0.67 
21.0 ± 
1.77 
30.36 ± 
0.36 
 
Data are represented as means ± SEM; n=9-10. GW, Gastrocnemius weight; BW, Body 
weight; TW, maximum twitch force; TET, maximum tetanic force; TPT, time to peak 
twitch tension; ½ RT, half relaxation time.  
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Summary and Future Work 
The results obtained from this thesis are important for understanding the role of 
Nrf2 in skeletal muscle and its impact on exercise-induced mitochondrial adaptations. 
This is a novel avenue of research since most studies investigating Nrf2 have either 
employed a cell culture approach to discern the intricate mechanisms of the Keap1-Nrf2 
interaction, or utilized tissues other than skeletal muscle to elucidate the importance of 
Nrf2 in various pathologies. However, no research has been devoted to understanding the 
impact of Nrf2 on skeletal muscle mitochondria and the ability of exercise to restore 
functional deficits.  
 Therefore, this thesis sought to investigate the following objectives: 1) To 
determine if Nrf2 is activated in skeletal muscle in response to exercise; 2) to examine 
whether Nrf2 is required for exercise-induced mitochondrial adaptations; 3) to evaluate 
the impact of Nrf2 on mitochondrial respiration and ROS production, and 4) to determine 
if age exacerbates the effect of the loss of Nrf2. Our results illustrate that the effect of 
Nrf2 is required to maintain normal mitochondrial respiration in control muscle. Further, 
we have shown that exercise results in the activation of Nrf2, and that it is required for 
mitochondrial content adaptations in response to training. However, we also established 
that exercise was capable of restoring the functional deficits in mitochondrial function 
and fatigue resistance in the Nrf2 KO mice, suggesting that Nrf2 is not required for 
exercise-induced adaptations in organelle function.   
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Given the present findings, future research should focus on the following:  
1. Exploring the ramifications of Nrf2 abrogation on mitochondrial physiology in 
skeletal muscle, specifically, indices such as protein import or permeability 
transition in the SS and IMF fractions.  
2. Elucidating the role of Nrf2 in mitochondrial clearance (i.e. mitophagy). Through 
the use of colchicine treatment and flow cytometry, potential disparities in 
mitophagy flux and membrane potential can be determined.  
3. Establishing the role of Nrf2 in the context of muscle disuse. Based on our 
supplementary findings we have shown that Nrf2 is reduced in response to 
denervation, which may partially be attributed to the marked increase observed in 
Keap1 protein expression. Moreover, studies can utilize the Nrf2 activator 
sulforaphane in an attempt to attenuate the atrophy response that ensues with 
denervation.  
4. Investigating the relationship of Nrf2 with other mitochondrial regulators such as 
PGC-1α, AMPK and SIRT1.  
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APPENDIX A – Data Tables and Statistical Analyses 
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week n=1 n=2 n=3 n=4 n=5 n=6 n=7 n=8 n=9 n=10 AVG SEM
1 6.04 5.14 3.07 2.05 1.34 9.81 12.44 6.7 3.03 5.51 1.23
2 26.2 9.22 8.01 6.05 3.76 0.24 24.8 17.94 8.46 7.04 11.17 2.78
3 10.61 8.98 8.84 7.81 8.14 0.36 24.64 27.9 18.82 12.76 12.89 2.67
4 4.84 16.43 22.83 19.75 25.4 0.37 27.02 24.67 17.07 5.95 16.43 3.01
5 10.19 5.44 28.22 21.52 9.91 0.49 15.02 17.31 10.94 3.06 12.21 2.70
6 7.06 5.67 14.93 16.04 2.99 0.12 15.34 8.12 3.41 8.19 1.97
KO T - wheel running distance (km/day)
week n=1 n=2 n=3 n=4 n=5 n=6 n=7 n=8 n=9 n=10 AVG SEM
1 6.19 2.53 13.83 7.01 3.3 18.23 12.65 1.92 4.6 8.21 1.92
2 23.26 1.11 19.75 0.17 7.81 23.97 27.13 21.59 11.03 19.69 15.09 3.09
3 19.04 0.74 11.03 0.53 15.02 21.52 18.2 18.61 11.74 10.29 12.94 2.33
4 15.72 2 15.96 1.94 28.53 11.61 16.29 15.83 8.89 18.05 12.97 2.50
5 16.81 1.89 14.17 6.7 21.29 10.2 2.77 10.2 3.26 15.34 9.70 2.09
6 9.16 1.22 8.27 3.92 6.94 0.67 8.87 10.22 1.06 14.08 5.59 1.44
WT T - wheel running distance (km/day)
Source of Variation P value P value summary Significant?
Interaction 0.4977 ns No
Genotype 0.9888 ns No
Training 0.0388 * Yes
2-WAY ANOVA 
weeks difference t P value Summary 
1 -0.765 1.048 P>0.05 ns
2 0.366 0.5013 P>0.05 ns
3 -1.116 1.488 P>0.05 ns
4 1.131 1.549 P>0.05 ns
5 -0.3512 0.4682 P>0.05 ns
6 -1.482 1.976 P>0.05 ns
Bonferroni Post-Hoc - WT vs KO at each time point 
Table 1A: Voluntary wheel running  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
89 
 
Table 1B: Body weight of WT and KO animals (UT vs. T; Young vs. Older mice).  
 
 
 
N WT UT WT T KO UT KO T WT A KO A
1 26.20 31.30 24.60 33.20 46.1 39.3
2 30.40 27.30 30.40 32.60 48.8 41.3
3 31.60 30.00 35.70 30.50 44.1 40.6
4 29.30 31 34.7 29.6 47.9 38.5
5 32.30 29.3 33.5 26.3 35 33.2
6 24.40 27.6 33.9 25.5 43.2 47.3
7 29.70 21.7 24 34.3 33.1
8 31.00 24 23.2 32.7
9 32.80 27.2 32.3 39.9
10 28.30 35.9 26.9
AVG 29.60 28.53 29.92 31.62 42.60 40.03
SEM 0.85 1.26 1.52 1.45 2.34 1.86
Body Weight (g)
Source of Variation P value P value summary Significant?
Interaction 0.2151 ns No
Genotype 0.8229 ns No
Training/Age < 0.0001 **** Yes
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 1.07 0.5408 P>0.05 ns
WT:UT vs. WT:Aged -13 5.963 P<0.05 ****
WT:UT vs. KO:UT -0.32 0.1617 P>0.05 ns
WT:UT vs. KO:T -2.022 0.9949 P>0.05 ns
WT:UT vs. KO:Aged -10.43 4.567 P<0.05 ***
WT:T vs. WT:Aged -14.07 6.454 P<0.05 ****
WT:T vs. KO:UT -1.39 0.7026 P>0.05 ns
WT:T vs. KO:T -3.092 1.521 P>0.05 ns
WT:T vs. KO:Aged -11.5 5.035 P<0.05 ***
WT:Aged vs. KO:UT 12.68 5.816 P<0.05 ****
WT:Aged vs. KO:T 10.98 4.924 P<0.05 ***
WT:Aged vs. KO:Aged 2.567 1.043 P>0.05 ns
KO:UT vs. KO:T -1.702 0.8374 P>0.05 ns
KO:UT vs. KO:Aged -10.11 4.427 P<0.05 ***
KO:T vs. KO:Aged -8.411 3.607 P<0.05 *
POST-HOC TEST 
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Table 1C: Gastroc weight of WT and KO animals (UT vs. T; Young vs. Older mice). 
 
 
 
N WT UT WT T KO UT KO T WT A KO A
1 6.45 5.88 6.38 6.72 4.49 5.11
2 5.49 5.64 5.72 6.26 4.04 5.21
3 5.51 5.57 5.41 5.77 5.33 5.69
4 6.62 5.87 5.07 5.78 3.59 3.84
5 5.42 5.94 5.34 5.89 5.49 4.70
6 5.66 5.18 5.40 5.37 3.68 4.57
7 5.62 6.27 6.25 4.96
8 5.55 4.83 5.65 5.14
9 6.13 6.25 5.73 4.71
10 6.29 5.52 6.17
AVG 5.87 5.69 5.71 5.62 4.44 4.85
SEM 0.14 0.14 0.14 0.21 0.33 0.26
Gastrocnemius weight/Body weight (mg/g)
Source of Variation P value P value summary Significant?
Interaction 0.3464 ns No
Genotype 0.7075 ns No
Training/Age < 0.0001 **** Yes
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.179 0.7171 P>0.05 ns
WT:UT vs. WT:Aged 1.437 4.986 P<0.05 ***
WT:UT vs. KO:UT 0.162 0.649 P>0.05 ns
WT:UT vs. KO:T 0.2518 0.9817 P>0.05 ns
WT:UT vs. KO:Aged 1.021 3.541 P<0.05 *
WT:T vs. WT:Aged 1.258 4.365 P<0.05 **
WT:T vs. KO:UT -0.017 0.0681 P>0.05 ns
WT:T vs. KO:T 0.07278 0.2838 P>0.05 ns
WT:T vs. KO:Aged 0.8417 2.92 P>0.05 ns
WT:Aged vs. KO:UT -1.275 4.424 P<0.05 ***
WT:Aged vs. KO:T -1.186 4.03 P<0.05 **
WT:Aged vs. KO:Aged -0.4167 1.293 P>0.05 ns
KO:UT vs. KO:T 0.08978 0.35 P>0.05 ns
KO:UT vs. KO:Aged 0.8587 2.979 P>0.05 ns
KO:T vs. KO:Aged 0.7689 2.614 P>0.05 ns
POST-HOC TEST 
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Table 2A: Endurance exercise capacity test – Distance to exhaustion 
 
 
 
N WT UT WT T KO UT KO T WT A KO A
1 1730 6254 2642 5234 1632 2042
2 2514 2514 2042 4490 1370 1587
3 2841 5937 2042 5731 1987 1107
4 2097 4057 1987 5731 1107 1779
5 2211 5331 2707 3891 2329 1681
6 2211 6147 2329 3417 1411 1987
7 1681 6147 2211 4761 1107
8 1681 5529 2514 6042
9 2042 2592 3194 6042
10
AVG 2112.00 4945.33 2407.56 5037.67 1563.29 1697.17
SEM 130.98 504.32 132.47 319.18 172.34 137.88
Distance to exhaustion (m)
Source of Variation P value P value summary Significant?
Interaction 0.9299 ns No
Genotype 0.4755 ns No
Training/Age < 0.0001 **** Yes
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -2833 7.2 P<0.05 ****
WT:UT vs. WT:Aged 548.7 1.304 P>0.05 ns
WT:UT vs. KO:UT -295.6 0.7511 P>0.05 ns
WT:UT vs. KO:T -2926 7.435 P<0.05 ****
WT:UT vs. KO:Aged 414.8 0.9429 P>0.05 ns
WT:T vs. WT:Aged 3382 8.039 P<0.05 ****
WT:T vs. KO:UT 2538 6.449 P<0.05 ****
WT:T vs. KO:T -92.33 0.2346 P>0.05 ns
WT:T vs. KO:Aged 3248 7.383 P<0.05 ****
WT:Aged vs. KO:UT -844.3 2.007 P>0.05 ns
WT:Aged vs. KO:T -3474 8.259 P<0.05 ****
WT:Aged vs. KO:Aged -133.9 0.2883 P>0.05 ns
KO:UT vs. KO:T -2630 6.684 P<0.05 ****
KO:UT vs. KO:Aged 710.4 1.615 P>0.05 ns
KO:T vs. KO:Aged 3341 7.593 P<0.05 ****
POST-HOC TEST 
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Table 2B: Endurance exercise capacity test—Time to exhaustion  
 
 
 
N WT UT WT T KO UT KO T WT A KO A
1 78 136 94 126 75 84
2 92 92 84 118 70 75
3 97 133 84 131 83 50
4 85 113 83 131 50 79
5 87 127 95 111 89 77
6 87 135 89 105 71 83
7 77 135 87 121 50
8 77 129 92 134
9 84 104 102 134
10
AVG 84.89 122.67 90.00 123.44 69.71 74.67
SEM 2.29 5.31 2.11 3.48 5.68 5.13
Time to exhaustion (min)
Source of Variation P value P value summary Significant?
Interaction 0.8245 ns No
Genotype 0.2862 ns No
Training/Age < 0.0001 **** Yes
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -37.78 6.931 P<0.05 ****
WT:UT vs. WT:Aged 15.17 2.604 P>0.05 ns
WT:UT vs. KO:UT -5.111 0.9378 P>0.05 ns
WT:UT vs. KO:T -38.56 7.074 P<0.05 ****
WT:UT vs. KO:Aged 10.22 1.678 P>0.05 ns
WT:T vs. WT:Aged 52.95 9.088 P<0.05 ****
WT:T vs. KO:UT 32.67 5.994 P<0.05 ****
WT:T vs. KO:T -0.7778 0.1427 P>0.05 ns
WT:T vs. KO:Aged 48 7.877 P<0.05 ****
WT:Aged vs. KO:UT -20.29 3.482 P<0.05 *
WT:Aged vs. KO:T -53.73 9.222 P<0.05 ****
WT:Aged vs. KO:Aged -4.952 0.7699 P>0.05 ns
KO:UT vs. KO:T -33.44 6.136 P<0.05 ****
KO:UT vs. KO:Aged 15.33 2.516 P>0.05 ns
KO:T vs. KO:Aged 48.78 8.005 P<0.05 ****
POST-HOC TEST 
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Table 2C: Endurance exercise capacity test – lactate production 
 
 
 
Lactate production (mM)
N Pre- Post- Pre- Post- Pre- Post- Pre- Post- Pre- Post- Pre- Post-
1 2.4 9.5 1.3 5.2 2.7 8.7 2.4 5.9 2.1 8.1 3.6 11.5
2 1.9 10.6 1.3 11.5 1.5 12.7 3.2 10.3 1.8 9.3 2.1 5.8
3 2 7.8 2.7 8.2 2.9 5.8 1.6 4.7 2.4 9.2 2.7 15
4 1.1 9 1.5 8.1 1.7 6.4 2.2 7.8 3 11.8 2.8 7.9
5 1.3 8.1 1.7 3.5 1.5 8.7 2.3 9.8 1.9 7.8 3.6 12.9
6 2.2 6 2.6 6.4 2.2 6.4 2.3 9.1 2.5 9.3 2.1
7 2.5 8.4 2 4 2.5 5.4 2.3 4 1.8 1.5 14.5
8 3.5 12.3 2.3 6.2 2.4 9.3 2.3 5.4
9 2.5 7.8 2.9 5.4 3.4 8.3 2.3 7.9
AVG 2.16 8.83 2.03 6.50 2.31 7.97 2.32 7.21 2.21 9.25 2.63 11.27
SEM 0.24 0.61 0.21 0.82 0.22 0.76 0.14 0.77 0.17 0.58 0.30 1.51
WT UT WT T KO UT KO T WT A KO A
Source of Variation P value P value summary Significant?
Interaction 0.0458 * Yes
Genotype 0.0079 ** Yes
Training/Age < 0.0001 **** Yes
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
UT:Pre- vs. UT:Post- -6.678 8.404 P<0.05 ****
UT:Pre- vs. T:Pre- 0.1222 0.1538 P>0.05 ns
UT:Pre- vs. T:Post- -4.344 5.467 P<0.05 ****
UT:Pre- vs. UT:Pre- -0.1556 0.1958 P>0.05 ns
UT:Pre- vs. UT:Post- -5.811 7.313 P<0.05 ****
UT:Pre- vs. T:Pre- -0.1667 0.2097 P>0.05 ns
UT:Pre- vs. T:Post- -5.056 6.362 P<0.05 ****
UT:Pre- vs. WT :Pre- -0.05873 0.06914 P>0.05 ns
UT:Pre- vs. WT :Post- -7.094 7.985 P<0.05 ****
UT:Pre- vs. KO :Pre- -0.473 0.5568 P>0.05 ns
UT:Pre- vs. KO :Post- -8.464 9.003 P<0.05 ****
UT:Post- vs. T:Pre- 6.8 8.557 P<0.05 ****
UT:Post- vs. T:Post- 2.333 2.936 P>0.05 ns
UT:Post- vs. UT:Pre- 6.522 8.208 P<0.05 ****
UT:Post- vs. UT:Post- 0.8667 1.091 P>0.05 ns
UT:Post- vs. T:Pre- 6.511 8.194 P<0.05 ****
UT:Post- vs. T:Post- 1.622 2.041 P>0.05 ns
UT:Post- vs. WT :Pre- 6.619 7.792 P<0.05 ****
UT:Post- vs. WT :Post- -0.4167 0.469 P>0.05 ns
POST-HOC TEST 
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Table 2D: COX Activity in WT and KO mice (UT vs. T; Young vs. Older mice) 
 
 
 
N WT UT WT T KO UT KO T WT A KO A
1 10.74 18.63 16.04 17.59 15.81 15.65
2 16.92 16.01 18.34 15.78 16.08
3 14.53 18.40 14.86 18.36 17.28 14.67
4 16.04 18.44 15.26 16.98 14.83 16.37
5 11.92 16.04 14.08 14.94 16.81 13.06
6 15.46 17.80 15.83 15.92 16.54 16.92
7 15.87 18.41 15.98 16.97 17.49
8
9
10
AVG 14.50 17.95 15.44 17.01 16.36 15.46
SEM 0.87 0.40 0.28 0.47 0.36 0.57
COX Activity U/g muscle
Source of Variation P value P value summary Significant?
Interaction 0.1411 ns No
Genotype 0.4949 ns No
Training/Age 0.0002 *** Yes
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -3.456 4.512 P<0.05 **
WT:UT vs. WT:Aged -1.866 2.535 P>0.05 ns
WT:UT vs. KO:UT -0.94 1.277 P>0.05 ns
WT:UT vs. KO:T -2.517 3.42 P<0.05 *
WT:UT vs. KO:Aged -0.9612 1.255 P>0.05 ns
WT:T vs. WT:Aged 1.59 2.076 P>0.05 ns
WT:T vs. KO:UT 2.516 3.285 P<0.05 *
WT:T vs. KO:T 0.939 1.226 P>0.05 ns
WT:T vs. KO:Aged 2.495 3.139 P>0.05 ns
WT:Aged vs. KO:UT 0.9257 1.258 P>0.05 ns
WT:Aged vs. KO:T -0.6514 0.8851 P>0.05 ns
WT:Aged vs. KO:Aged 0.9045 1.181 P>0.05 ns
KO:UT vs. KO:T -1.577 2.143 P>0.05 ns
KO:UT vs. KO:Aged -0.02119 0.02766 P>0.05 ns
KO:T vs. KO:Aged 1.556 2.031 P>0.05 ns
POST-HOC TEST 
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Table 2E: Nrf2 Activation in response to exhaustive exercise  
 
 
Table 3A: Muscle fatigability (acute in situ stimulation) 
 
 
N CON Acute EX
1 1 2.62
2 1 1.23
3 1 0.94
4 1 1.66
5 1 0.99
6 1 2.14
7 1 1.25
AVG 1.55
SEM 0.24
Fold-Change (Exercise vs. Control)
Unpaired t test P value P value summary Significantly different? (P < 0.05) One- or two-tailed P value? t, df
0.0397 * Yes Two-tailed t=2.307 df=12
Contraction Time (Sec)
0 100 100 100 100 100 100 97.28 100
30 95 86 81 85.91 80.91 85.97 89.67 81
60 93 76 73 68.58 71.84 82.91 90.69 52.9
90 92 67 68 58.85 60.62 75 83.11 49.37
120 92 66 56 52.82 59.1 73.47 77.24 47.95
150 93 61 52 59.94 52.77 61.19 70.52 47.5
180 96 60 55 50.07 53.27 61.51 66.27 46.82
210 83 54 54 40.91 52.77 62.83 54.87 48.06
240 75 48 47 35.27 44.27 53.19 48.92 38.73
270 71 44 43 30.11 47.37 51.44 45.06 39.87
300 69 39 43 30.26 50.46 52.96 44.53 37.26
330 67 42 42 33.35 51.77 58.55 40.71 34.75
360 64 41 39 27.37 45.49 55.05 33.69 33.51
390 54 32 33 21.29 38.82 55.92 30.88 30.88
420 45 33 34 17.38 37.94 43.64 30.79 26.51
450 39 32 32 19.41 35.56 38.49 30.79 23.44
480 36 29 29 14.9 34.99 38.37 30.03 25.82
510 33 26 29 14.04 33.69 29.28 30.07 27.53
540 30 30 28 11.71 41.75 37.17 29.27 25.25
WT UT
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Contraction Time (Sec)
0 100 100 100 100 100 100 100 100 100
30 78.83 93 86.53 81.83 83.9 86.99 57.49 89.77 83.68
60 78.5 92 78.65 75.12 74.78 78.92 54.75 83.09 76.63
90 74.19 90 69.99 73.2 64.71 68.5 46.68 79.58 71.96
120 69.11 86 70.06 66 60.35 62.13 43.74 73.6 69.34
150 66.37 77 69.95 64.53 55.69 63.5 47.93 68.81 66.68
180 66.56 73 61.39 64.03 55.64 58.15 48.63 65.8 64.87
210 61.19 69 54.91 61.77 50.28 56.28 45.58 58.64 57.58
240 59.15 62 53 60.05 45.07 49.36 46.88 55.31 53.47
270 55.75 58 47.95 58.04 44.86 48.57 45.18 53.08 48.07
300 53.29 60 48.26 52.64 40.82 44.07 48.31 50.98 50
330 50.52 50 49.59 59.8 40.76 44.36 47.72 50.39 48.34
360 46.66 45 45.77 60.34 40.48 39.92 48.24 47.02 47.46
390 42.3 40 41.89 50.71 39.15 34.49 45.63 44.83 40.57
420 34.98 41 39.84 51 39.38 37.78 39.26 38.88 40.17
450 39.93 44 40.49 49.71 38 39.57 38.67 37.62 40.13
480 37.89 32 45.53 51.8 33.3 37.92 44.47 37.12 38.76
510 36.3 31 45.16 52.97 35.06 36.42 37.7 36.07 41.05
540 36.49 36 44.1 54.94 33.68 37.21 41.86 35.75 40.29
WT T
Contraction Time (Sec)
0 100 100 100 100 100 100 100 100 100 100
30 78 96 76 81.15 100.44 56.26 77.38 84.98 77.56 83.48
60 75 80 55 68.85 92.85 46.85 76.41 68.39 54.23 72.33
90 78 73 38 61.75 75.67 40.14 49.51 56.32 55.39 59.16
120 78 69 34 52.36 56.96 32.34 40.59 46.69 46.79 49.21
150 77 68 40 50.63 54.29 29.33 52.73 45.91 44.8 46.6
180 76 77 37 50.29 34.41 23.22 36.1 44.32 44.38 37.1
210 71 66 35 46.87 32.22 20.62 41.29 32.4 30.06 33.65
240 63 61 30 43.83 29.68 19.43 34.69 35.92 27.83 27.38
270 64 56 31 44.13 19.96 10.72 21.06 33.76 28.72 25.35
300 63 55 29 44.68 19.42 13.41 22.33 36.35 28.34 24.91
330 60 57 30 41.8 23.92 19.92 25.07 30.31 29.56 26.03
360 59 50 30 35.21 18.57 10.91 14.19 30.39 32.99 22.59
390 52 50 24 32.17 18.13 10.11 21.77 25.93 23.84 22.44
420 34 46 20 35.34 16.11 15.02 17.41 19.04 26.25 21.54
450 31 44 21 32.58 16.74 14.22 19.03 18.54 27.98 20.57
480 33 43 20 26.92 14.34 9.2 16.01 23.78 26.44 19.83
510 35 44 19 24.85 15.05 12.91 14.95 18.24 29.32 20.12
540 35 40 23 22.15 15.76 13.01 15.94 20.87 27.37 22.14
KO UT
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Table 3B: Linear regression (fatigue rates between WT UT vs. KO UT) 
 
Contraction Time (Sec)
0 100 100 100 100 100 100 100 100
30 93 86 73.12 78.43 81.97 84.13 83 84
60 73 74 61.19 77.27 70.04 73.07 69 74
90 72 66 55.06 69.95 65.95 61.62 64 66
120 72 65 48.22 70.99 64.65 54.47 56 60
150 70 58 43.04 70.72 60.56 43.59 55 55
180 55 56 41.14 68.26 59.26 39.6 47 51
210 57 51 41.22 67.04 56.25 37.77 43 45
240 47 55 41.34 64.63 55.17 37.58 41 41
270 50 50 40.81 63.28 53.45 38.87 40 40
300 52 51 40.52 60.75 52.08 39.25 37 39
330 54 48 40.81 62.11 52.16 38.11 37 38
360 47 46 38.53 65.54 51.07 39.22 37 37
390 51 40 37.7 67.03 49.07 32.52 35 35
420 51 47 35.62 65.16 42.39 30.77 32 31
450 51 52 34.8 65.67 47.34 31.68 27 30
480 48 48 32.43 65.03 46.62 31.04 31 30
510 49 50 31.46 64.63 45.47 28.79 31 30
540 46 53 31.98 66.32 44.9 29.93 32 29
KO T
WT UT KO UT
Best-fit values
Slope -0.2787 ± 0.04176 -0.4038 ± 0.04026
Y-intercept when X=0.0 96.23 ± 3.069 96.09 ± 2.959
X-intercept when Y=0.0 345.3 238
1/slope -3.588 -2.477
95% Confidence Intervals
Slope -0.3632 to -0.1941 -0.4848 to -0.3227
Y-intercept when X=0.0 90.01 to 102.4 90.13 to 102.0
X-intercept when Y=0.0 277.9 to 470.6 207.2 to 283.7
Goodness of Fit
R square 0.5396 0.6769
Sy.x 11.21 12.08
Is slope significantly non-zero?
F 44.53 100.6
DFn, DFd 1.000, 38.00 1.000, 48.00
P value < 0.0001 < 0.0001
Deviation from zero? Significant Significant
Data
Number of X values 5 5
Maximum number of Y replicates 8 10
Total number of values 40 50
Number of missing values 10 0
Equation Y = -0.2787*X + 96.23 Y = -0.4038*X + 96.09
Linear Regression
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Table 3C: Force production (% of initial at 5 minutes of stimulation) 
 
 
 
 
 
 
 
 
N WT UT WT T KO UT KO T 
1 39 53.29 29 52
2 43 60 44.68 51
3 30.26 48.26 19.42 40.52
4 50.46 52.64 13.41 60.75
5 52.96 40.82 22.33 52.08
6 44.53 44.07 36.35 39.25
7 37.26 48.31 28.34 37
8 50.98 24.91 39
9 50
10
AVG 42.50 49.82 27.31 46.45
SEM 2.95 1.84 3.47 3.05
Force production at 5 minutes 
ANOVA TABLE SS df MS P-value 
Between 2436 3 811.9 < 0.0001
Within 1803 28 64.4
Total 4239 31
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T -7.323 1.811 P>0.05 ns
WT UT vs. KO UT 15.19 3.657 P<0.05 **
WT UT vs. KO T -3.954 0.952 P>0.05 ns
WT T vs. KO UT 22.51 5.773 P<0.05 ****
WT T vs. KO T 3.369 0.8639 P>0.05 ns
KO UT vs. KO T -19.15 4.771 P<0.05 ***
POST-HOC TEST 
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N WT UT WT T KO UT KO T 
1 30 36.49 35 46
2 30 36 40 53
3 28 44.1 23 31.98
4 11.71 54.94 22.15 66.32
5 41.75 33.68 15.76 44.9
6 37.17 37.21 13.01 29.93
7 29.27 41.86 15.94 32
8 25.25 35.75 20.87 29
9 40.29 27.37
10 22.14
AVG 29.14 40.04 23.22 41.64
SEM 3.12 2.17 3.38 4.73
Force production at 9 minutes 
ANOVA TABLE SS df MS P-value 
Between 2058 3 686.1 0.0006
Within 2791 31 90.04
Total 4850 34
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T -10.89 2.362 P>0.05 ns
WT UT vs. KO UT 5.62 1.249 P>0.05 ns
WT UT vs. KO T -12.5 2.634 P>0.05 ns
WT T vs. KO UT 16.51 3.787 P<0.05 **
WT T vs. KO T -1.606 0.3482 P>0.05 ns
KO UT vs. KO T -18.12 4.025 P<0.05 **
POST-HOC TEST 
Table 3D: Force production (% of initial at 9 minutes of stimulation) 
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N WT UT WT T KO UT KO T 
1 9.44 4.95 4.07 12.55
2 10.05 7.59 9.84 8.72
3 3.64 5.42 7.83 8.95
4 8.02 7.11 6.96 6.57
5 3.01 3.19 8.99 13.33
6 2.78 14.64 5.98 5.85
7 7.63 5.65 5.46 10.11
8
9
10
AVG 6.37 6.94 7.02 9.44
SEM 1.18 1.40 0.77 1.06
SS Respiration State 4
ANOVA TABLE SS df MS P-value 
Between 16.5 3 5.499 0.6879
Within 276.8 25 11.07
Total 293.3 28
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T -0.5686 0.3197 P>0.05 ns
WT UT vs. KO UT -0.6514 0.3663 P>0.05 ns
WT UT vs. KO T -2.002 1.162 P>0.05 ns
WT T vs. KO UT -0.08286 0.04659 P>0.05 ns
WT T vs. KO T -1.433 0.8322 P>0.05 ns
KO UT vs. KO T -1.35 0.7841 P>0.05 ns
POST-HOC TEST 
Table 4A: SS mitochondrial State 4 Respiration (n atoms O2/mg protein/ min) 
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N WT UT WT T KO UT KO T 
1 22.06 17.66 31.69 27.66
2 25.12 24.27 30.55 27.51
3 23.33 21.11 34.31
4 24.15 24.48 16.25 29.44
5 11.89 26.95 30.98
6 20.48 32.73 19.24 11.32
7 15.55 25.7 16.85 20.31
8 20.34
9
10
AVG 19.88 25.02 22.62 25.23
SEM 2.11 1.70 2.79 2.63
SS Respiration State 3
ANOVA TABLE SS df MS P-value 
Between 265.3 3 88.42 0.6142
Within 1191 25 47.64
Total 1456 28
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T -6.89 1.868 P>0.05 ns
WT UT vs. KO UT -2.366 0.6412 P>0.05 ns
WT UT vs. KO T -7.107 1.989 P>0.05 ns
WT T vs. KO UT 4.524 1.226 P>0.05 ns
WT T vs. KO T -0.2166 0.06064 P>0.05 ns
KO UT vs. KO T -4.741 1.327 P>0.05 ns
POST-HOC TEST 
Table 4A (Cont): SS mitochondrial State 3 Respiration (n atoms O2/mg protein/ 
min) 
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N WT UT WT T KO UT KO T 
1 13.62 15.73 6.12 16.79
2 9.71 13.87 6.22 5.67
3 10.77 18.97 10.19 15.54
4 19.6 12.68 7.58 19.04
5 20.51 20.68 11.55 21.04
6 16.35 24.86 14.02 10.64
7 12.4 19.78 13.41 17.02
8 19.49 19.18 6.56 24.62
9 11.16 12.19 7.33 20.29
10 18.97 21.46 9.17 10.57
AVG 15.26 17.55 9.46 16.12
SEM 1.32 1.41 1.16 1.81
IMF State 4 Respiration
ANOVA TABLE SS df MS P-value 
Between 429 3 143 0.0005
Within 686.8 36 19.08
Total 1116 39
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T -2.682 1.373 P>0.05 ns
WT UT vs. KO UT 6.043 3.094 P<0.05 *
WT UT vs. KO T -0.864 0.4423 P>0.05 ns
WT T vs. KO UT 8.725 4.467 P<0.05 ***
WT T vs. KO T 1.818 0.9307 P>0.05 ns
KO UT vs. KO T -6.907 3.536 P<0.05 **
POST-HOC TEST 
Table 4B: IMF mitochondrial State 4 Respiration (n atoms O2/mg protein/ min) 
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N WT UT WT T KO UT KO T 
1 56.78 60.41 49.03 43.87
2 41.49 73.22 40.44 67.34
3 48.82 56.04 45.61 67.45
4 64.21 75.84 40.68 65.75
5 63.47 73.93 62.68 63.04
6 62.63 76.11 71.09 58.85
7 41.11 72.51 65.42 63.58
8 51.05 76.63 33.41 79.63
9 52.17 56.78 20.09 61.39
10 56.04 65.92 45.6 58.85
AVG 53.78 69.05 51.05 62.98
SEM 2.67 2.89 4.83 2.84
IMF State 3 Respiration 
ANOVA TABLE SS df MS P-value 
Between 2700 3 899.9 0.0004
Within 4141 36 115
Total 6841 39
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T -14.96 3.119 P<0.05 *
WT UT vs. KO UT 6.372 1.329 P>0.05 ns
WT UT vs. KO T -9.198 1.918 P>0.05 ns
WT T vs. KO UT 21.33 4.448 P<0.05 ***
WT T vs. KO T 5.764 1.202 P>0.05 ns
KO UT vs. KO T -15.57 3.246 P<0.05 *
POST-HOC TEST 
Table 4B (Cont): IMF mitochondrial State 3 Respiration (n atoms O2/mg protein/ 
min) 
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N WT UT WT T KO UT KO T 
1 5518.55 9513.23 12240.9 3632.1
2 4236.03 7679.32 4855.01 4862.4
3 13419.1 9954.88 5263.31 5377.39
4 5788.87 5409.09 5464.9 7089.41
5 7699.18 12881.2 4512.4 3086.08
6 2474.03 5104.54
7 4343.21
8
9
10
AVG 7332.34 7985.29 6467.30 4785.02
SEM 1619.29 1497.65 1452.75 492.32
SS ROS State 4
ANOVA TABLE SS df MS P-value 
Between 34850000 3 11620000 0.9241
Within 1482000000 20 74090000
Total 1517000000 23
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T -653 0.1253 P>0.05 ns
WT UT vs. KO UT 865 0.1589 P>0.05 ns
WT UT vs. KO T -2289 0.4664 P>0.05 ns
WT T vs. KO UT 1518 0.2912 P>0.05 ns
WT T vs. KO T -1636 0.3519 P>0.05 ns
KO UT vs. KO T -3154 0.6427 P>0.05 ns
POST-HOC TEST 
Table 4C: SS Mitochondrial State 4 ROS production (ROS/n atoms O2/min) 
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N WT UT WT T KO UT KO T 
1 2928.62 3488 1851.09 2151.72
2 2678.59 2525.53 1635.03 1558.5
3 7474.3 2403.39 2252.56 1226.89
4 2172.28 1905.11 2743.68 1741.79
5 1827.38 1976.26 7064.88 1651.59
6 1361.06 5042.31
7 1922.34
8 2348.62
9
10
AVG 3416.23 2276.56 3109.45 2205.47
SEM 1032.51 295.07 1006.75 423.61
SS ROS State 3
ANOVA TABLE SS df MS P-value 
Between 6404000 3 2135000 0.5153
Within 54250000 20 2713000
Total 60660000 23
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T 1140 1.143 P>0.05 ns
WT UT vs. KO UT 306.8 0.2945 P>0.05 ns
WT UT vs. KO T 1211 1.289 P>0.05 ns
WT T vs. KO UT -832.9 0.8351 P>0.05 ns
WT T vs. KO T 71.09 0.07992 P>0.05 ns
KO UT vs. KO T 904 0.9628 P>0.05 ns
POST-HOC TEST 
Table 4C (Cont): SS Mitochondrial State 3 ROS production (ROS/n atoms O2/min) 
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N WT UT WT T KO UT KO T 
1 1797.83 1333.3 3383.73 1416.28
2 2167.44 1841.06 3638.13 3467.04
3 2277.78 1168.57 2162.4 1867.51
4 1572.01 2164.89 3556.15 1329.1
5 1800.88 1309.54 2862.86 1324.51
6 1753.74 945.8 2164.88 2747.92
7 1296.61 1287.01 2348.71 1369.96
8 2944.6 1370.88 3688.68 636.55
9 2061.99 1168.38 5920.34 1062.03
10 1168.57 1228.14 1448.37
AVG 1884.15 1398.83 2975.69 1666.93
SEM 162.53 124.68 238.12 264.72
IMF State 4 ROS
ANOVA TABLE SS df MS P-value 
Between 20310000 3 6772000 < 0.0001
Within 20710000 35 591793
Total 41030000 38
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T 502.4 1.46 P>0.05 ns
WT UT vs. KO UT -1419 4.014 P<0.05 **
WT UT vs. KO T 217.2 0.6314 P>0.05 ns
WT T vs. KO UT -1921 5.435 P<0.05 ****
WT T vs. KO T -285.2 0.8289 P>0.05 ns
KO UT vs. KO T 1636 4.628 P<0.05 ***
POST-HOC TEST 
Table 4D: IMF Mitochondrial State 4 ROS production (ROS/n atoms O2/min) 
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N WT UT WT T KO UT KO T 
1 672.37 357.72 622.03 980.86
2 704.16 329.13 782.34 285.08
3 632.42 559.21 815.26 427.37
4 635.86 465.53 855.12 555.98
5 619.72 538.39 727.01 706
6 669.55 297.81 568.65 964.07
7 480.2 377.92 725.15 416.49
8 643.98 351.13 1372.52 263.16
9 706.68 486.32 770.26 446.96
10 559.21 220.25 220.66
AVG 632.42 418.13 808.51 526.66
SEM 21.72 31.93 87.31 86.95
IMF State 3 ROS
ANOVA TABLE SS df MS P-value 
Between 837606 3 279202 0.0004
Within 1260000 35 35993
Total 2097000 38
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT UT vs. WT T 234.1 2.759 P>0.05 ns
WT UT vs. KO UT -171.8 1.971 P>0.05 ns
WT UT vs. KO T 105.8 1.246 P>0.05 ns
WT T vs. KO UT -405.9 4.657 P<0.05 ***
WT T vs. KO T -128.3 1.512 P>0.05 ns
KO UT vs. KO T 277.6 3.185 P<0.05 *
POST-HOC TEST 
Table 4D (Cont): IMF Mitochondrial State 3 ROS production (ROS/n atoms 
O2/min) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
108 
 
N WT UT WT T KO UT KO T 
1 2.39 1.41 1.51 1.25
2 1.74 1.52 0.82 0.86
3 1.83 1.34 0.84 0.95
4 1.38 1.17 0.33 0.34
5 1.55 1.37 0.33 0.35
6 1.34 1.19 0.32 0.28
AVG 1.71 1.33 0.69 0.67
SEM 0.16 0.06 0.19 0.17
NQO1
POST-HOC TEST 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.3717 1.733 P>0.05 ns
WT:UT vs. KO:UT 1.013 4.724 P<0.05 ***
WT:UT vs. KO:T 1.033 4.818 P<0.05 ***
WT:T vs. KO:UT 0.6417 2.992 P<0.05 *
WT:T vs. KO:T 0.6617 3.085 P<0.05 *
KO:UT vs. KO:T 0.02 0.09324 P>0.05 ns
Source of Variation P value P value summary Significant?
Interaction 0.26 ns No
Genotype < 0.0001 **** Yes
Training 0.2114 ns No
2-WAY ANOVA 
Table 5A: NQO1 Protein expression in WT and KO mice (UT vs. T) 
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N WT UT WT T KO UT KO T 
1 0.91 1.75 3.64 3.18
2 4.58 3.56 3.53 8.23
3 5.55 6.70 3.00 6.57
4 8.02 3.77 3.07 2.12
5 2.58 2.73 3.74 4.53
6 2.73 4.58 5.00 7.32
7 3.29 4.26 2.72 7.35
AVG 3.95 3.91 3.53 5.62
SEM 0.88 0.59 0.28 0.89
HO-1
Source of Variation P value P value summary Significant?
Interaction 0.1439 ns No
Genotype 0.3714 ns No
Training 0.1605 ns No
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T 0.04429 0.04443 P>0.05 ns
WT:UT vs. KO:UT 0.4229 0.4242 P>0.05 ns
WT:UT vs. KO:T -1.663 1.668 P>0.05 ns
WT:T vs. KO:UT 0.3786 0.3798 P>0.05 ns
WT:T vs. KO:T -1.707 1.713 P>0.05 ns
KO:UT vs. KO:T -2.086 2.092 P>0.05 ns
POST-HOC TEST 
Table 5B: HO-1 Protein expression in WT and KO mice (UT vs. T) 
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N WT UT WT T KO UT KO T 
1 1.62 2.21 1.74 3.66
2 3.37 3.22 1.47 2.16
3 0.80 3.22 0.68 0.81
4 0.75 3.11 0.57 0.93
5 1.48 3.83 3.36 2.02
6 4.26 5.32 3.37 5.74
7 4.21 4.18 3.17 2.02
8 2.20 1.46 2.99 5.48
9 4.63 5.11 5.66 6.11
AVG 2.05 3.49 1.87 2.55
SEM 0.59 0.42 0.51 0.76
G6PD
Source of Variation P value P value summary Significant?
Interaction 0.8089 ns No
Genotype 0.7614 ns No
Training 0.1605 ns No
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -0.9267 1.188 P>0.05 ns
WT:UT vs. KO:UT 0.03444 0.04417 P>0.05 ns
WT:UT vs. KO:T -0.6233 0.7993 P>0.05 ns
WT:T vs. KO:UT 0.9611 1.232 P>0.05 ns
WT:T vs. KO:T 0.3033 0.3889 P>0.05 ns
KO:UT vs. KO:T -0.6578 0.8434 P>0.05 ns
POST-HOC TEST 
Table 5C: G6PD Protein expression in WT and KO mice (UT vs. T) 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
111 
 
N WT UT WT T KO UT KO T 
1 1.95 1.97 2.58 5.57
2 4.64 4.15 3.13 4.23
3 1.97 4.17 4.61 4.00
4 4.18 6.37 2.85 2.11
5 3.59 8.58 5.82 4.19
6 6.98 9.19 7.91
7 3.18 3.42 4.71 2.24
8 2.75 2.85 4.04 7.44
9 5.40 5.58 4.78 4.61
AVG 3.85 5.14 4.49 4.30
SEM 0.55 0.84 0.55 0.61
GPx1
Source of Variation P value P value summary Significant?
Interaction 0.2622 ns No
Genotype 0.8788 ns No
Training 0.4047 ns No
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT:UT vs. WT:T -1.293 1.427 P>0.05 ns
WT:UT vs. KO:UT -0.6433 0.7097 P>0.05 ns
WT:UT vs. KO:T -0.4499 0.4814 P>0.05 ns
WT:T vs. KO:UT 0.65 0.717 P>0.05 ns
WT:T vs. KO:T 0.8435 0.9027 P>0.05 ns
KO:UT vs. KO:T 0.1935 0.2071 P>0.05 ns
POST-HOC TEST 
Table 5D: GPx1 Protein expression in WT and KO mice (UT vs. T) 
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N WT Y WT A KO A
1 5.36 7.06 0.79
2 4.14 7.8 1.06
3 4.29 4.65 1.19
4 3.93 6.01 0.9
5 3.54 4.56 0.69
6 4.65 10.46 2.2
7 7.54 8.06
AVG 4.78 6.94 1.14
SEM 0.51 0.79 0.22
NQO1 Young vs. Older Mice
Bonferroni Mean Diff. t-value P-value Summary 
WT Y vs. WT A -2.164 2.688 P<0.05 *
WT Y vs. KO A 3.64 4.344 P<0.05 **
WT A vs. KO A 5.805 6.927 P<0.05 ****
POST-HOC TEST 
Table 6A: NQO1 Protein Expression WT and KO (Young vs. Older mice) 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
ANOVA TABLE SS df MS P-value 
Between 110.1 2 55.03 < 0.0001
Within 38.57 17 2.269
Total 148.6 19
ANOVA 
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N WT Y WT A KO A
1 3.81 9.31 7.47
2 1.92 10.24 11.72
3 3.68 4.02 7.52
4 7.8 5.01 4.74
5 5.68 6.13 9.88
6 7.17 13.65
7 8.98
AVG 4.58 7.27 9.16
SEM 1.00 0.88 1.32
HO-1 Young vs. Older Mice
ANOVA TABLE SS df MS P-value 
Between 57.49 2 28.75 0.0381
Within 105.3 15 7.017
Total 162.7 17
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT Y vs. WT A -2.688 1.733 P>0.05 ns
WT Y vs. KO A -4.585 2.859 P<0.05 *
WT A vs. KO A -1.898 1.288 P>0.05 ns
POST-HOC TEST 
Table 6B: HO-1 Protein Expression WT and KO (Young vs. Older mice) 
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N WT Y WT A KO A
1 2.23 6.06 4.2
2 3.8 5.35 4.01
3 6.74 2.04 3.18
4 1.06 3.93 3.86
5 2.17 2.6 1.86
6 4.21 5.24
7 6.03
AVG 3.46 4.32 3.73
SEM 1.23 0.60 0.46
G6PD Young vs. Older Mice
ANOVA TABLE SS df MS P-value 
Between 57.49 2 28.75 0.0381
Within 105.3 15 7.017
Total 162.7 17
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT Y vs. WT A -1.117 1.151 P>0.05 ns
WT Y vs. KO A -0.525 0.5231 P>0.05 ns
WT A vs. KO A 0.5921 0.6422 P>0.05 ns
POST-HOC TEST 
Table 6C: G6PD Protein Expression WT and KO (Young vs. Older mice) 
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N WT Y WT A KO A
1 8.34 8.19 7.05
2 6.75 6.74 8.98
3 6.07 3.54 4.99
4 3.55 3.73 3.27
5 4.43 5.94 7.09
6 9.14 10.45 6.72
7 12.53
AVG 7.05 7.30 6.35
SEM 0.67 1.26 0.80
GPx1 Young vs. Older Mice
ANOVA TABLE SS df MS P-value 
Between 3.891 2 1.946 0.378
Within 110 16 6.878
Total 113.9 18
ANOVA 
Bonferroni Mean Diff. t-value P-value Summary 
WT Y vs. WT A -0.9229 0.6325 P>0.05 ns
WT Y vs. KO A 0.03 0.01981 P>0.05 ns
WT A vs. KO A 0.9529 0.6531 P>0.05 ns
POST-HOC TEST 
Table 6D: GPx1 Protein Expression WT and KO (Young vs. Older mice) 
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N WT UT WT T KO UT KO T
1 7.00 5.46 6.21 6.63
2 6.47 3.69 7.27 4.15
3 6.69 9.03 4.12 7.10
4 5.31 7.44 7.05 4.79
5 4.81 6.53 2.01 7.49
6 3.74 5.94 3.37 6.47
7 8.48 5.27 5.64 9.56
8 4.68 7.76 6.10 9.18
9 6.23 7.30 7.51 6.84
10 4.55 7.19 5.02
AVG 5.80 6.56 5.43 6.91
SEM 0.45 0.48 0.57 0.59
Maximum TET per mg of muscle (mN/mg)
Source of Variation P value P value summary Significant?
Interaction 0.4977 ns No
Genotype 0.9888 ns No
Training 0.0388 * Yes
2-WAY ANOVA 
Bonferroni Mean Diff. t-value P-value Summary
WT:UT vs. WT:T -0.765 1.048 No ns
WT:UT vs. KO:UT 0.366 0.5013 No ns
WT:UT vs. KO:T -1.116 1.488 No ns
WT:T vs. KO:UT 1.131 1.549 No ns
WT:T vs. KO:T -0.3512 0.4682 No ns
KO:UT vs. KO:T -1.482 1.976 No ns
POST-HOC TEST 
Table 7: Maximum TET per mg of muscle  
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Supplementary 1	
	
	
	
	
	 	
Figure S1. Following 7 days of denervation (A) TA mass (B) COX activity and the (C) protein 
expression of keap1 were measured. *P<0.05 Den vs. Con. Data are expressed as means ± SEM.  
119 
 
Supplementary 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S2. Protein expression for (A) Nrf2 and (B) Keap1 were examined in different 
fibre types in order to determine if there was any correlation between the Nrf2-Keap1 
pathway and mitochondrial content. The ratio of Keap1:Nrf2 protein was highest in the 
most oxidative muscle types, suggesting that the pathway is relatively inactive when 
mitochondrial content is high. The opposite ratio was observed in the low oxidative 
FTW muscle. Data are expressed as means ± SEM; ANOVA was used for analysis; 
Nrf2 *P<0.05 FTW vs. STR and HRT, #P<0.05 FTR vs. STR and HRT; keap1 *P<0.05 
STR vs. Fast twitch fibres; $P<0.05 HRT vs. all fibre types.  
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Supplementary 3 
 
 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure S3. Male Sprague-Dawley rats were subjected to 3 and 7 days of 
denervation. Nrf2 (A) and Keap1 (B) protein levels were examined. Nrf2 protein 
was reduced at day 7, however, Keap1 protein was significantly increased 
following 3 and 7 days of denervation. *P<0.05 Den vs. Con. Data are expressed 
as means ± SEM.  
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CYTOCHROME C OXIDASE ASSAY FOR MICROPLATE READER 
 
J. Biol. Chem. 189:665, 1951,  
Meth. Biochem. Anal. 2:427, 1955,  
Meth. Enzymol. 10:245, 1967. 
 
THEORY: 
Tissue extract containing cytochrome c oxidase is added to the test solution 
containing fully reduced cytochrome c. The rate of cytochrome c oxidation is measured 
over time as a reduction in absorbance at 550 nm. The reaction is carried out at 30o C.  
 
REAGENTS: 
 
1. 20 mM KCN;  MW= 65.12, 13.02 mg/10 ml dH2O 
 
2. 100 mM K-Phosphate Buffer 
 
- make up 0.1 M KH2PO4;     MW= 136.09  
= 13.6 g/1000 ml 
 (pH approx. 5) 
 (rm. temp) 
- make up 0.1 M K2HPO4.3H2O;    MW= 174.18 
= 17.4 g/1000 ml 
 (pH approx. 8) 
 (rm. temp) 
- mix in equal proportions, pH to 7.0 
 
3. 10 mM K-Phosphate Buffer 
 
- dilute 0.1 M KPO4 Buffer prepared above 1:10 with ddH2O (eg. 10 ml buffer + 
90 ml ddH2O) 
 
4.  Extraction Buffer (100 mM Na-K-Phosphate, 2 mM EDTA; pH 7.2) 
 
- 500 ml 0.1 M Na2HPO4. 2H2O;  
 
   Combine 8.9 g sodium phosphate with 0.372 g EDTA up to 
500 ml. 
                 
- 200 ml 0.1 M KH2PO4;                               
 
Combine 2.7 g potassium phosphate with 0.149 g EDTA up 
to 200 ml. 
 
- combine both solutions and pH to 7.2      
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5. Test Solution (reduced cytochrome c, 2 mg/ml), for 10 ml (enough for 36 microplate 
wells); 
- weigh out 20 mg of horse heart cytochrome c (Sigma, C-2506) in a scintillation 
vial 
 
- add 1 ml of 10 mM KPO4 buffer and dissolve cytochrome c 
 
- make up a small volume of 10 mg/ml sodium dithionite-10 mM KPO4 stock 
solution (make fresh each experiment and use within twenty minutes) 
 
- add 40 µl of the dithionite stock solution to the test solution and observe red-
orange colour change 
 
- add 8 ml of ddH2O 
 
- add 1 ml of 100 mM KPO4 buffer. 
 
PROCEDURE: 
 
1. Place  powdered muscle samples in liquid N2. 
 
2. Add 50 µl of extraction Buffer to 1.5 ml Eppendorf tubes in the aluminum block 
on ice.  (One Eppendorf per sample).  
 
3.  Add 5-7.5 mg tissue to each tube, recording exact tissue mass.  Mix by tapping.  
 
4.  Add the volume of Extraction Buffer required to obtain a 20-fold dilution.   
 
5. Add a stir bar and mix for 15 min. Make up Test Solution during this time and 
wrap in foil.  
 
6.  Sonicate each tube 3 x 3 seconds, cleaning the probe between samples. 
 
7. Pipette some of 20-fold sample extract into new Eppendorf tube and add volume 
of Extraction Buffer required to obtain an 80-fold dilution.  (eg. 50 µl of 20-fold 
extract + 150 µl Ext. Buffer = 200 µl of 80-fold sample extract).  Keep 80-fold 
sample extract tube on ice for duration of experiment  
 
8.  Add 270 µl of Test Solution into 4-8 wells of 96-well microplate and incubate at 
30°C for 10 minutes to stabilize the temperature and absorbance. 
 
9. Open KC4 plate reader program (on Triton).  Select CONTROL icon, then PRE-
HEATING tab, enter 30°C and select ON.  (Do not run assay until KC4 
temperature has reached 30°C.) 
 
10. Select WIZARD icon, then READING PARAMETERS icon. 
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§ Select Kinetic for Reading Type. 
§ Select Absorbance for Reader and 550 nm for wavelength (drop-down 
menu). 
§ Select Sweep for Read Mode. 
§ Select 96 Well Plate (default) for Plate Type. 
§ Enter first and last well to be read (eg. A1 and A4 if reading 4 samples 
simultaneously). 
§ Select Yes and Pre-heating and enter 30 for Temperature Control. 
§ For Shaking enter 0 for both intensity and duration (shaking is not 
necessary and it will delay the first reading).  
§ Do not select either of the two options for Pre-reading. 
§ Click on the KINETIC… rectangular tile to open the Kinetic window. 
§ Enter run time (1 minute is recommended) and select MINIMUM for 
Interval time (under these conditions the minimum Interval time should be 
3 seconds). 
§ Select Allow Well Zoom During Read to see data in real time (optional). 
§ Under Scales, checkmarks should appear for both Auto check boxes.  Do 
not select Individual Well Auto Scaling. 
§ Press OK to return to Reading Parameters window.  Press OK to return to 
Wizard window.  Press OK.  Do not save the protocol. 
 
11. Set the multipipette to 250 µl and secure 4-8 yellow tips on the white projections 
(make sure they are on tight and all at the same height). 
 
12. In a second, clean 96 well plate, pipette samples into 4-8 empty wells (start with 
A1).  Recommended volumes: 30 µl of 80-fold extract for Mixed Gastroc, 10 µl 
for Heart.  Adjust volumes according to oxidative capacity of the tissue.  (eg.  25 
µl for Red Gastrocnemius and 35 µl for White Gastrocnemius).  
 
13. Remove microplate with Test Solution in 4-8 wells from the incubator (as long as 
it has been incubating for 10 minutes).  Place this plate beside the plate with the 
sample extracts in it. 
 
14. On KC4 program, select the READ icon and press the START READING icon, 
then press the READ PLATE button.  A box will appear that says, “Insert plate 
and start reading”.  Do not press OK yet, but move the mouse so that the cursor 
hovers over the OK button. 
 
15. Using the multipipette (set to 250 µl) carefully draw up the Test Solution.  Make 
sure the volume is equal in all the pipette tips, and that no significant air bubbles 
have entered any of the tips. 
 
16. Pipette the Test Solution into the wells with the sample extracts (the second 
plate).  As soon as all the Test Solution has been expelled from the tips (do not 
wait for the second push from the multipipette), place the plate onto the tray of the 
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plate reader and with the other hand on the mouse, press the OK button.  (Speed at 
this point is paramount, as there is an unavoidable latency period between the 
time of pressing the OK button and the time of the first reading.)  
 
17. If desired, add 5 µl KCN to one of the wells to measure any absorbance changes 
in the presence of the CYTOX inhibitor. 
  
18. Once reading is complete, hold the CTRL key on the keyboard, and use the mouse 
to click once on each of the squares corresponding to a well that had sample in it.  
Once all the desired wells have been highlighted by a black square (up to a 
maximum of 8 wells), let go of the CTRL key and a large graph will appear with 
lines on it representing each sample.   
 
19. To obtain the rate of change of absorbance over different time periods, select 
Options and enter the amount of time for which you would like a rate of change of 
absorbance to be calculated.  The graph, along with one rate (at whichever time 
interval is selected) for each sample can be printed on a single sheet of paper, and 
the results can be saved. 
 
20. The delta absorbance will appear in units of mOD/min and the number given will 
be negative.  Convert this to OD/min by dividing by 1000 and omit the negative 
sign in the calculation.  (eg. if Mean V: -394.8 mOD/mn, then use 0.395 OD/min) 
 
 
CALCULATION:   CYTOX activity (µmole/min/g tissue) 
 
        =  delta absorbance/min x total volume (ml) x 80 (dilution)   
           18.5 (µmol/ml extinction coeff.) x sample vol (ml) 
 
 
Example Calculation: 
 
30 µl of 80-fold sample extract 
250 µl of Test Solution 
Mean V: -284.2 mOD/mn 
 
COX activity =  (.284)(.280)(80)   
        (18.5)(.030) 
 
= 11.5 µmol/min/g tissue 
 
= 11.5 U/g tissue 
 
  
Filename: COX ASSAY 
MICROPLATE 
Tissue Heart Mixed Gastroc 
Weight (mg) 5 mg 7.5 mg 
Vol. for 20-fold 100 µl 150 µl 
Remove, put in 
new Eppendorf 50 µl 75 µl 
Vol. needed for 
80-fold 
Add 150 µl    
of extract. 
buffer 
Add 225 µl    
of extract. 
buffer 
Final Volume of 
80-fold 200 µl 300 µl 
Vol. of 80-fold 
per well 10 µl 30 µl 
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PROTOCOL: GENOTYPING MICE USING PCR 
 
Background:  This protocol is designed to detect sequences in the murine genome that 
differ between wild-type and null animals using polymerase chain reaction amplification.  
PCR is a rapid, inexpensive and simple way of copying specific DNA fragments from 
minute quantities of source DNA material.  There are basically 3 procedural steps 
involved in PCR: 
 
1) Denaturation:  DNA is heated to high temperature to separate the DNA double helix 
to single strands making them accessible to primers.  During denaturation (94° C, 30sec), 
the DNA strands separate to form single strands.   
 
2) Annealing: The reaction mixture is cooled down.  Primers anneal to the 
complementary regions in the DNA template strands, and double strands are formed 
again between primers and complementary sequences.  During annealing (60°C, 30sec) 
one primer binds to one DNA strand and another binds to the complementary strand.  The 
annealing sites of the primers are chosen so that they will prime DNA synthesis in the 
region of interest during extension.  
 
3) Extension: The DNA polymerase synthesizes a complementary strand.  The enzyme 
reads the opposing strand sequence and extends the primers by adding nucleotides in the 
order in which they can pair.  During extension (72°C, 45sec), DNA synthesis proceeds 
through the target region and for variable distances into the flanking region, giving rise to 
long fragments of variable lengths.  The whole process is repeated over and over. 
 
 
 
 
Fig.1: Schematic of basic PCR procedures. 
 
The DNA polymerase, known as Taq polymerase, is named after the hot-spring 
bacterium Thermus aquaticus from which it was originally isolated.  The enzyme can 
withstand the high temperature needed for DNA-strand separation.  The cycle of heating 
and cooling is repeated over and over, stimulating the primers to bind to the original 
sequences and to newly synthesized sequences.  The enzyme will continue to extend 
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primer sequences.  This cycling of temperatures results in copying and then copying of 
copies, leading to an exponential increase in the number of copies of specific sequences.  
Because the amount of DNA placed in the tube at the beginning is very small, almost all 
the DNA at the end of the reaction cycles are copied sequences. 
 
The reaction products are then separated by gel electrophoresis and visualized with the 
use of ethidium bromide. 
 
Reagents 
 
Lysis Buffer (pH=8.0) 
 
10 mM Tris HCl  (0.121g/100ml) 
150 mM NaCl  (0.8766g/100ml) 
20 mM EDTA  (0.744g/100ml) 
Autoclave for 30min and store at room temperature. 
 
Supermix 
 
Sigma Jumpstart REDtaq Ready Mix PCR Reaction Mix (P0982) 
Product contains 20 mM Tris-HCl, pH 8.3, 100mM KCl, 4 mM MgCl2, 0.002% gelatin, 
0.4 mM each dNTP (dATP, dCTP, dGTP, TTP), inert dye, stabilizers, 0.06 unit/µl Taq 
DNA polymerase, JumpStart Taq antibody. 
 
Primers 
 
Forward and Reverse for WT and Null Stock Concentration 500 pmol/µl 
Working Concentration of Primers (10X dilution): 50 pmol/ul 
To make up 50 pmol/µl: use 5 µl of 500 pmol/µl stock and add 45µl of sterile water 
 
Proteinase K 
ProK- concentration of 1mg/ml 
 
Reagents for Agarose Gel Electrophoresis of PCR product 
 
Agarose 50XTAE 
50 X TAE 242 g TRIS 
1X TAE (dilute 50X TAE with stH2O) 500ml dH2O 
10mg/ml EtBr 100ml 0.5M EDTA (pH 8.0) 
Sterile water 57.1ml Glacial Acetic Acid 
 Make up to 1L and autoclave  
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DNA EXTRACTION FROM EAR CLIPPINGS 
 
1. Make (fresh) 10:1 mixture of lysis buffer to ProK (@concentration of 1mg/ml-fresh) 
2. Add 20 µl of this mixture to a 1.5 ml sterile eppendorf tube. 
3. Obtain ear clipping from animal, add to tube and vortex (ensure ear clipping is 
immersed in solution). 
4. Incubate in a 55 °C water bath (no higher than 60 °C) for 30min, vortexing every 15 
minutes. 
5. Add 180 µl sterile distilled water. 
6. Place in boiling water for 5 minutes (use hot plate) and then vortex. 
7. Store at -20°C, or use immediately for PCR 
 
PCR method 
 
1. Make mastermix for each of the primers you will be using.   
Mastermix contains: 25 µl of Supermix sample 
1 µl of Forward Primer per sample 
1 µl of Reverse Primer per sample 
Enough sterile distilled water for a volume per sample of 50 µl. 
 
2. For each sample use 48 µl of mastermix and 2 µl of template DNA extracted from 
procedure described above.  Add 1 drop of mineral oil to each PCR tube to prevent 
evaporation of sample during cycling. 
 
3. Cycling times: Initial Denaturation  94°C  2min 
    
35 cycles: Denaturation 94°C  30sec 
Annealing  60°C  30sec 
Extension  72°C  45sec     
    
Final Extension  72°C  5min 
   Hold      4°C     
 
Running PCR product on gel 
 
1. Loading buffer is already included in Supermix. 
 
2. Preparation of a 1.2% agarose gel.  For large gel system: 3.6g Agarose, 6 ml 50X TAE 
and volumed up to 300 ml with sterile H2O.  Mix solution and note weight followed by 
boiling in microwave.  Remove periodically to mix during boiling procedure in 
microwave.  Upon complete dissolving of agarose and a homogenous and releatively  
clear agarose solution, weigh solution and replace lost amount of evaporated H2O. Add 
25µl of EtBr (10mg/ml), slightly cool solution in room temperature (5-10min), then pour 
into caster.   
For small gel system: 1.92g Agarose, 3.2 ml 50X TAE, and 156.8ml st H2O; follow same 
procedure as noted above.  Only add 8 µl of EtBr (10mg/ml). 
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Electrophoresis Running Buffer: 1X TAE: 40 ml of 50X TAE made up to 2L with H2O.    
 
3. Run 10 µl of PCR product reaction on either a small or large 1.2% agarose gel for 1hr 
@ approximately 90V. 
 
Example of Experimental Setup/Procedure for PCR Genotyping (15 mice) 
 
1. Make up mastermix for both wild-type and null primers for the number of animals 
required for genotyping. 
  
Mastermix(proportions) 
 
A) WT Mastermix B) Null Mastermix  
 
25µl Supermix 25µl Supermix   
1µl Forward Primer WT 1µl Forward Primer Null 
1µl Reverse Primer WT 1µl Reverse Primer Null 
23µl Sterile Water 23µl Sterile Water 
50µl Total 50µl Total 
 
X 17 reactions (over estimate, since 15 animals required) 
 
 
 Total Mastermix 
 
A) WT Mastermix B) Null Mastermix  
 
425µl Supermix 425µl Supermix   
17µl Forward Primer WT 17µl Forward Primer Null 
17µl Reverse Primer WT 17µl Reverse Primer Null 
391µl Sterile Water 391µl Sterile Water 
850µl Total 850µl Total 
 
1. Label PCR tubes with 1N and 1W to represent each animal and each mastermix, 
respectively. 
 
2. Place 48 µl of null mastermix in PCR tubes with N designation and 48 µl of wild-type 
mastermix in PCR tubes with W designation. 
 
3. Add 2µl of DNA template from animals into the appropriate PCR tubes i.e. DNA 
isolated from animal #1 into 1 N and 1W. 
 
4. Include negative controls using dH2O instead of DNA template with both Null and 
wild-type mastermix i.e. 2 µl of dH2O into PCR tubes with 48 µl of WT mastermix and 2 
µl of dH2O into PCR tubes with 48 µl of Null mastermix. 
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5.  Add 1 drop of mineral oil to each tube and place tubes into thermocycler for 35 cycles.  
Use file # 29 on thermocycler for the initial 2 min denaturation then STOP this program.  
Use file # 30 for repeated cycles.  Scroll through the settings in File # 29 and change the 
settings to achieve: 
 
Denaturation 94°C 30sec 
Annealing 60°C 30sec 
Extension 72 °C 45sec 
 
Then link this file (#29) to file #33 which is the final extension of 72°C for 10min 
(protocol states 5min but 10min does not make a difference).  This will be followed by a 
hold cycle at 4°C.  Samples can be left holding overnight if necessary. 
 
6.  Prepare either large gel or small gel or both depending on number of samples.  Load 
PCR products onto gel and run for 1-1.5 hours. 
 
7.  Visualize PCR products using UV lightbox in the molecular core facility.  Null PCR 
product should be about 600bp whereas WT PCR product will be about 300bp.  If animal 
#1 displays a band for both the Null and the WT, the animal is a heterozygote.  If animal 
#1 exhibits only a Null band but no WT band then the animal is a homozygous null.  If 
the animal displays a wild-type but no Null band then the animal is homozygous wild-
type. 
 
Fig.2: Typical agarose gel displaying PCR products and animal genotypes.  
 
 
 
 
Genotype 
30A-hetero 31E-hetero 33C-hetero 
30B-hetero 32A-hetero 34-hetero 
31A-null 32B-hetero 
31B-hetero 32C-hetero 
31C-hetero 33A-wild-type 
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IN SITU STIMULATION 
 
Animals are anesthetized (60 mg/kg) and prepared for in situ stimulation according to the 
following procedure:  
 
A. Surgical Preparation: 
 
Hindlimb Muscles 
 
1. The right hindlimb was skinned, and prepared for electrical stimulation. 
 
2. A hole is made with forceps under the achilles tendon. This is used to start the 
incision for the removal of the hamstring muscles medially and laterally.  Vessels 
are cauterized to prevent blood loss.  
 
3. The sciatic nerve is carefully isolated to prevent irritation.  It is tied off and cut 
proximally, leaving a nerve stump 2-3 cm long for stimulation.  
 
4. A string is tied around the achilles tendon through the hole (step 2) and used to 
secure a pin attaching the cut achilles (and thus the gastrocnemius-plantaris-soleus 
muscle group) to a strain gauge.   
 
B.  Stimulation: 
 
1. The animal is placed ventral side down in the in situ preparation with the 
stabilization pin positioned in a brass block, and the achilles tendon attached to 
the strain gauge via the metal pin. 
 
2. Body temperature is maintained using a heating pad. Muscle temperature is 
maintained at 37oC with a heat lamp, and monitored with a surface thermometer 
(Yellow Springs Instrument Co., Inc. Ohio). The muscle belly is covered with 
Saran wrap over the temperature probe to prevent tissue dehydration.  It is 
periodically squirted with 0.9% NaCl. 
 
3. The appropriate resting tension of the muscle is established by generating a 
length-tension curve. 
 
4. The voltage required to produce maximum tension can be determined with either 
indirect nerve stimulation or direct muscle stimulation. Muscles are stimulated 
directly with platinum wire electrodes inserted parallel to the long axis of muscle 
fibers, or indirectly by attaching the nerve to the coiled platinum electrodes being 
careful not to stretch it. 
 
5. The time to peak tension and 1/2 relaxation time can be determined  from single 
twitches, elicited using supramaximal voltage.  
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6. Muscle endurance performance is evaluated using continuous stimulation of the 
muscle over 5-15 minutes at, for example, 1 Hz stimulation frequency, using 
supramaximal voltage and 0.1 ms duration.   
 
7. Gastrocnemius muscle can then be removed and freeze clamped for biochemical 
analysis.  
 
 
 
 
MITOCHONDRIAL ISOLATION FROM SKELETAL MUSCLE 
References:  Cogswell et al. Am J Physiol, 1993, 264: C388-C389 
                   Krieger et al. J Appl Physiol, 1980, 48: 23-28 
 
 
Reagents  
All buffers are set to pH 7.4 and stored at 4 °C  
 
- Buffer 1       - Buffer 1 + ATP  
100 mM KCl       Add 1 mM ATP to Buffer 1  
5 mM MgSO4  
5 mM EDTA  
50 mM Tris base  
 
- Buffer 2      - Resuspension medium  
100 mM KCl       100 mM KCl  
5 mM MgSO4      10 mM MOPS  
5 mM EGTA       0.2% BSA  
50 mM Tris base  
1 mM ATP  
 
- Nagarse protease (Sigma, P-4789) 
10 mg/ml in Buffer 2  
Make fresh for each isolation, keep on ice  
 
Procedure  
 
1. Remove the tibialis anterior (TA) muscle from the rat, and put it in a beaker 
containing 5 ml Buffer 1, on ice immediately.  
2. Place TA on a watch glass that is also on ice and trim away fat and connective 
tissue. Proceed to thoroughly mince the muscle sample with forceps and scissors, 
until no large pieces are remaining.  
3. Place the minced tissue in a plastic centrifuge tube and record the exact weight of 
tissue.  
4. Add a 10-fold dilution of Buffer 1 + ATP to the tube.  
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5. Homogenize the samples using the Ultra-Turrax polytron with 40% power output 
and 10 s exposure time. Rinse the shaft with 0.5 ml of Buffer 1 + ATP to help 
minimize sample loss.  
6. Using a Beckman JA 25.50 rotor, spin the homogenate at a centrifuge setting of 
800 g for 10 min. This step divides the IMF and SS mitochondrial subfractions. 
The supernate will contain the SS mitochondria and the pellet will contain the 
IMF mitochondria. 
SS mitochondrial isolation:  
7. Filter the supernate through a single layer of cheesecloth into a second set of 50 
ml plastic centrifuge tubes.  
8. Spin tubes at 9000 g for 10 min. Upon completion of the spin discard the 
supernate and gently resuspend the pellet in 3.5 ml of Buffer 1 + ATP. Since the 
mitochondria are easily damaged, it is important that the resuspension of the 
pellet is done carefully.  
9. Repeat the centifugation of the previous step (9000 g for 10 min) and discard the 
supernate.  
10. Resuspend the pellet in 200 µl of Resuspension medium, being gentle so as to 
prevent damage to the SS mitochondria. Some extra time is needed during this 
final resuspension to ensure the SS pellet is completely resuspended.  
11. Keep the SS samples on ice while proceeding to islolate the IMF subfraction.  
 
IMF mitochondrial isolation: 
7. Gently resuspend the pellet (from step 6) in a 10-fold dilution of Buffer 1 + ATP 
using a teflon pestle.  
8. Using the Ultra-Turrax polytron set at 40% power output, polytron the 
resuspended pellet for 10 s. Rinse the shaft with 0.5 ml of Buffer 1 + ATP.  
9. Spin at 800 g for 10 min and discard the resulting supernate.  
10. Resuspend the pellet in a 10-fold dilution of Buffer 2 using a teflon pestle.  
11. Add the appropriate amount of nagarse. The calculation for the appropriate 
volume is 0.025 ml/g of tissue. Mix gently and let stand exactly 5 min.  
12. Dilute the nagarse by adding 20 ml of Buffer 2.  
13. Spin the diluted samples at 5000 g for 5 min and discard the resulting supernate.  
14. Resuspend the pellet in a 10-fold dilution of Buffer 2. Gentle resuspension is with 
a teflon pestle.  
15. Spin the samples at 800 g for 10 min. Upon the completion of the spin, the 
supernate is poured into another set of 50 ml plastic tubes (on ice), and the pellet 
is discarded.  
16. Spin the supernate at 9000 g for 10 min. The supernate is discarded and the pellet 
is resuspended in 3.5 ml of Buffer 2.  
17. Spin samples at 9000 g for 10 min and discard the supernate.  
18. Gently resuspend the pellet in 300 µl of Resuspension medium.  
 
Background: Mitochondria are the primary source of reactive oxygen species (ROS) to 
the cell.  It is estimated that about 2% of total cellular oxygen is converted ROS by the 
inappropriate reduction of molecular oxygen by intermediate members of the electron 
transport chain (ETC).  ROS are damaging molecules that are capable of compromising 
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the integrity of macromolecules within the mitochondria and may lead to overall 
organelle dysfunction.  In particular, mtDNA may be prone to attack by ROS because 1) 
mtDNA is located in close proximity to the ETC, 2) mtDNA lacks the protective sheath 
of histones compared to nuclear DNA and, 3) mitochondria have an insufficient repair 
system for mtDNA mutations.   ROS can exist in a variety of molecular permutations 
such as superoxide  (O2-), hydroxyl radical (OH-) and hydrogen peroxide (H2O2).    
DCF (2,7,-dichloro-fluorescein; Fig.1) is a reagent that is non-fluorescent until the 
acetate groups are removed by intracellular esterases and oxidation occurs within the 
mitochondria (Fig.1).  DCF is oxidized by all of the different forms of ROS and this can 
be detected by monitoring the increase in fluorescence with a fluorometric plate reader.  
The appropriate plate reader filter settings for fluorescein are the following: Excitation 
485/20 and Emission 528/20 (Fig.2).  
        
 
  Fig.1-DCF molecule and oxidation of DCF resulting in fluorescence 
 
    
Fig.2-Absorption and Emission Spectra of oxidized dye       \ 
        
KC4 Software Settings: The Settings icon in the upper left corner allows the alteration of 
various parameters.  Once clicked, another window appears, click on the Wizard Icon.  In 
this window there will be a variety of components that can be altered.  The following are 
the parameters that need to be changed in order to utilize the DCF and measure time-
dependent ROS production from isolated mitochondria: 
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1) Top Middle Panel- Absorbance, Fluorescence, Luminescence- choose Fluorescence 
2) Top Left Panel- End Point, Kinetic, Spectrum- choose Kinetic 
3) Top Middle Panel- Click on larger box labeled Kinetic to set parameters- Run Time 
1:20:00, Interval 5:00 (takes a measure every 5 minutes), click on box labeled Allow 
Well Zoom during Read, and also click on box labeled Individual Well Auto Scaling- 
The Well Zoom and Auto scaling allows for monitoring each individual well during the 
experiment and scales it appropriately. 
4) Middle Panel-Filter Set- Choose #1, then set the excitation to 485/20, and emission to 
528/20 as described above.  The optics position should be set to the TOP (i.e. readings 
are taken from the top of the well) and the sensitivity is set at 50 (depending upon the 
amount and/or nature of the sample).  
5) Plate-Type-choose 96-well plate, choose which wells are to be read i.e. A1-C12. 
6) Shaking-Intensity set at 1, Duration set at 15s and then click the box that is labeled 
before every reading (it shakes the samples for 15 s before every reading). 
7) Temperature Control- Click on the box indicating YES , also click on box labeled pre-
heating, and put 37°C into the temperature box. 
 
DCF Reagent and VO2 Buffer 
 
DCF (2,7,-dichlorodihydrofluorescein diacetate) reagent MW=487.29 (Molecular Probes 
D-399/ 100mg) 
 
1°STOCK- Make up 50mM Stock Solution in EtOH- 24 mg/ml- only make about 500ul 
i.e. 14 mg per 500ul EtOH. Wrap stock solution in aluminum foil and limit exposure to 
light since DCF is light-sensitive. 
 
Working Stock Solution-2° STOCK- Dilute 50mM by 100-fold by taking 10ul and 
adding 990 ul of EtOH to attain a 500uM DCF Stock Solution.  This will be the DCF 
concentration used to add to the reaction mixture. 
 
VO2 Buffer- refer to mitochondrial respiration protocol 
 
Procedure 
 
1. SS and IMF mitochondria are isolated as described in the mitochondrial isolation 
protocol.  Alternatively, frozen mitochondrial extracts can also be used.  
 
2. Determine the volume necessary for 50ug of mitochondria.  Typical volumes should 
range between 5-40ul depending upon concentration of mitochondrial extracts. 
 
3. Final concentration of DCF is 50uM.  The total volume of the reaction mixture is 
250ul.  Thus, 25ul of DCF is used in the reaction mixture since this represents a 10-
fold dilution.  Set up table (as shown below) and determine the amount of VO2 buffer 
necessary to make each of the reaction mixtures equal to 250 ul.  (Remember to 
include a control with only VO2 buffer and DCF reagent as in Well #1 shown below)           
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  SS 
       
Control Mar.23 Mar.25 Mar.29 
  Well #1 Well #2 Well #3 Well #4 
ug mito 0 50 50 50 
ul mito 0.00 11.77 9.80 17.24 
VO2 Buff 225.00 213.23 215.20 207.76 
DCF (50uM) 25 25 25 25 
Total Volume 250 250 250 250 
 
4. Once table is complete and volumes for all samples have been determined, place the 
frozen (already thawed) or fresh mitochondria, VO2 buffer and DCF (500uM) into a 
37°C circulating water bath for 5-10 min. 
 
5. Pipette the volume of VO2 buffer required for each of the samples followed by the 
mitochondrial samples into the appropriate wells of a 96-well plate.  In addition, 
include a well (usually in the corner well) with only 250 ul of VO2 buffer to monitor 
temperature (see below). Place the 96-well plate with the VO2 buffer and mitochondria 
into a 37°C incubator.  Using the YSI temperature probe, place the recording electrode 
into the well with buffer only and monitor the temperature until 37°C is reached.  
During this time, be sure that the KC4 software is set up and that the Biotek plate 
reader is pre-heating to 37°C. 
 
6. Once mitochondria and buffer have reached temperature (37°C), take the DCF out of 
the circulating water bath (37°C) and quickly add the DCF to each of the reaction 
mixtures.   Following addition of DCF, promptly place the plate into the Biotek plate 
reader for fluorescence measurement and start the KC4 program by pressing READ 
plate on the upper left portion of the computer screen.  Kinetic program will operate 
for 1 h and 20 min.   
 
 
 
 
IN VIVO TREADMILL RUN 
 
DAY 1: Acclimatize  
1. Place the mice on the treadmill and allow them to sit idle for 5 minutes. Also 
ensure that the treadmill is set to a 10% incline.  
2. Adjust the speed to 5m/min for 5 minutes 
3. Stop the treadmill and place the mice back in their respective cages 
DAY 2: Acclimate 
1. If lactate is required, collect blood samples prior to beginning the second day of 
treadmill acclimatization.   
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2. Place the mice on the treadmill and allow them to sit idle for 5 minutes 
3. Adjust the speed to 5m/min for 5 minutes, followed by 10m/min for 10 minutes 
4. Stop the treadmill and place the mice back in their respective cages 
DAY 3: Exhaustive Run  
1. Exhaustive run is outlined as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NRF2 ACTIVATION ASSAY 
 
Company: Active Motif, Carlsbad, CA, USA 
Product: Trans AM Nrf2 
Cat #: 50296 
             
**Note: All buffers and reagents are provided and prepared according to the 
manufacturers protocol. Adapted protocol is listed below-- 
             
Step 1: Binding of Nrf2 to its consensus sequence 
1. Add 40µl complete binding buffer to each well to be used 
2. Sample wells: Add 10µl of sample diluted in complete lysis buffer per well. 
Manufacturer recommends using 5-20µg of nuclear extract diluted in complete 
lysis buffer per well 
3. Positive control wells: Add 5µg of the provided positive control extract diluted 
in 10µl of complete lysis buffer per well (2µl of control extract in 8µl of complete 
lysis buffer per well) 
4. Blank wells: Add 10µl complete lysis buffer only per well 
5. Use the provided adhesive cover to seal the plate. Incubate for 1 hour at room 
temperature with mild agitation (100 rpm on a rocking platform) 
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6. Wash each well 3 times with 200µl 1X washing buffer. For each wash, flick the 
plate over a sink to empty the wells, then tap the inverted plate on absorbent paper 
towels 
Step 2: Binding of primary antibody 
1. Add 100µl of diluted Nrf2 antibody (1:1000 dilution in 1X antibody binding 
buffer) to each well being used 
2. Cover the plate and incubate for 1 hour at room temp. without agitation 
3. Wash the well 3 times as described above.  
Step 3: Binding of secondary antibody 
1. Add 100µl of diluted HRP-conjugated antibody (1:1000 dilution in 1X antibody 
binding buffer) to all wells being used 
2. Cover the plate and incubate for 1 hour at room temperature without agitation 
3. During this incubation, place the developing solution at room temperature 
4. Wash the wells 4 times as described above.  
 
Step 4: Colorimetric reaction 
1. Add 100µl developing solution to all wells being used 
2. Incubate 2-15 minutes at room temperature protected from direct light. Monitor 
the blue colour development in the sample and positive control wells until it turns 
medium to dark blue. Do not overdevelop.  
3. Add 100 µl stop solution. In presence of the acid, the blue colour turns yellow. 
4. Read absorbance on a spectrophotometer within 5 minutes at 450nm with a 
reference wavelength of 655nm.  
References 
1. Pi, J. et al. (2007) Free Radical Biol Med 42(12): 1797-1806. 
2. Lee, O-H, et al. (2007) J Biol Chem 282(50): 36412-36420 
3. Theodore, M. et al. (2008) J Biol Chem 283(14): 8984-8994 
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SDS POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
PROTEAN BIO-RAD SYSTEM 
 
Reagents 
 
1. Acrylamide/Bis-Acrylamide, 30% Solution 37.5:1 (BioShop 10.502) 
a. Store at 4°C 
2. Under Tris Buffer 
a. 1M Tris-HCl, pH 8.8 (60.5g/500ml) 
b. Store at 4°C 
3. Over Tris Buffer 
a. 1M Tris-HCl, pH 6.8 (12.1g/100ml) 
b. Bromophenol Blue (for colour) 
c. Store at 4°C 
4. Ammonium Persulfate (APS) 
a. 10% (w/v) APS in ddH20 (1g/10ml) 
b. Stored at 4°C 
5. Sodium Dodecyl Sulfate (SDS) 
a. 10% (w/v) in ddH20 (1g/10ml) 
b. Store at room temperature 
6. TEMED (Sigma T-9281) 
7. Electrophoresis Buffer, pH 8.3 (10L) 
a. 25mM Tris 30.34g, 192mM Glycine 144g, 0.1% SDS 10g 
b. Volume to 10L with ddH20 
c. Store at room temperature 
8. 6X SDS 
a. Warm 100% glycerol in water bath at 65°C for 30 minutes 
b. Combine 1.2g SDS, 0.06g Bromophenol Blue, 3mls of 1M Tris, pH 6.8 
and 1ml of ddH20 and stir at 4°C for 5 minutes 
c. Add 3mls of 100% glycerol, stir and aliquot mixture. 
d. Store at -20°C 
e. Add 5% (v/v) ß-mercaptoethanol (Sigma M6250) to 6X SDS just prior to 
use 
9. tert-Amyl alcohol ReagentPLus, 99% (Sigma 152463) 
 
Procedure 
 
1. Prepare electrophoresis rack: 
a. Clean glass plates thoroughly with soap followed by 95% ethanol then 
ddH20.  
b. Dry carefully with a kimwipe.  
c. Assemble glass plates as shown below: 
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d. Check the seal y adding a small volume of ddH20 then pour off and let 
dry.  
2. Prepare separating gels: 
a. Mini Protean 3 Bio-Rad System volumes: 
 
 8% 10% 12% 15% 18% 
Acrylamide 2.7 ml 3.3 ml 4.0 ml 5.0 ml 6.0 ml 
ddH20 4.1 ml 3.5 ml 2.8 ml 1.8 ml 0.8 ml 
Under Tris 3.0 ml 3.0 ml 3.0 ml 3.0 ml 3.0 ml 
SDS 100µl 100µl 100µl 100µl 100µl 
APS 100µl 100µl 100µl 100µl 100µl 
TEMED 10µl 10µl 10µl 10µl 10µl 
 
b. Mix the contents of the separating gel without adding APS or TEMED. 
Stir.  
c. Add APS and TEMED. Stir.  
d. Slowly pour the entire volume of the solution into the space between the 
two plates while keeping plates tilted to prevent bubble formation. 
e.  Add tert-Amyl alcohol to coat top surface of gel solution. 
f. Allow 30 minutes for gel polymerization.  
g. Remove tert-Amyl alcohol by pouring it off and remove any remainder 
with a kimwipe. Rinse with ddH20. 
3. Prepare stacking gel: 
a. For a single mini gel use the following volumes: 
 
Acrylamide 500 µl 
Over Tris 625 µl 
ddH20 3.75 ml 
SDS 50 µl 
APS 50 µl 
TEMED 7.5 µl 
 
b. Mix the contents of the stacking gel without adding APS or TEMED. Stir.  
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c. Add APS and TEMED. Stir.  
d. Using a Pasteur pipette slowly add the entire volume from the beaker in 
between the plates.  
e. Add comb for desired number of wells. 
f. Allow 30 minutes for gel polymerization. 
 
4. Prepare samples: 
a. Turn of the block heater to 95ºC.  
b. Pipette required volume of sample into new eppendorf with 6X SDS (1 
volume of sample to 1/6 sample volume of 6X SDS). Keep samples on ice 
until all samples are prepared. 
c. Briefly spin each sample to bring volume to the bottom of the eppendorf. 
d. Incubate each sample at 95 ºC for 5 minutes in the heating block to 
denature the proteins.  
e. Briefly spin again to return volume to the bottom of the eppendorf. 
 
5. Assemble Mini-PROTEAN gel caster system: 
a. See images below: 
 
 
b. If you are only running one gel a plastic rectangular pseudo plate must be 
clamped on the other side of the caster.  
c. Fill with electrophoresis buffer between the plates and outside of the 
plates in the chamber.  
d. Slowly remove the comb using both hands (one on each side) by pulling 
the comb straight upwards.  
e. Fix any wells that are deformed using a small spatula.  
f. Clean out the wells using a syringe filled with electrophoresis buffer.  
g. Withdraw the entire volume of the sample using a Hamilton syringe. Inject 
volume slowly into the bottom of the well.  
 
6. Gel electrophoresis  
a. Immediately after all samples are loaded place the lid on the gel chamber. 
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b. Place positive and negative plugs into the power supply and turn on power 
supply.  
c. Set power supply to 120V. Gel will run for ~2 hours depending on percent 
gel made. 
d. When the bromophenol blue has run off the bottom of the gel turn off the 
power supply. Remove plugs from power supply and remove lid. 
e. Prepare for electrotransfer of proteins from the gel to nitrocellulose 
membrane.  
 
 
 
 
WESTERN BLOTTING AND IMMUNODETECTION 
 
Reagents 
 
1. Transfer Buffer 
a. 0.025M Tris-HCl pH 8.3  12.14g 
b. 0.15M Glycine   45.05g 
c. 20% Methanol   800ml 
d. make up to 4L with ddH20 
e. store at 4°C 
2. Ponceau S stain 
a. 0.1% (w/v) Ponceau S  
b. 0.5% (v/v) Acetic Acid 
c. Store at room temperature 
3. Wash Buffer 
a. Tris-HCl pH 7.5  12g 
b. NaCl   58.5g 
c. 0.1% Tween  10ml 
d. Store at room temperature 
4. Blocking Solution 
a. 5% (w/v) skim milk power in wash buffer OR 
b. 5% (w/v) BSA in wash buffer 
5. Enhanced Chemiluminescence Fluid (ECL; Santa Cruz sc-2048) 
6. Film/Developer/Fixer 
 
Procedure 
 
1. Transfer Procedure 
a. Remove electrophoresis plates from chamber and separate the plates. 
b. Cut away unnecessary parts of the gel using a spatula and measure 
remaining gel size. 
c. Using a paper cutter cut 6 pieces of Whatman paper per gel to the same 
size as the gel. Wearing gloves cut nitrocellulose membrane (GE 
Healthcare RPN303D) to the dimensions of the gel.  
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d. Assemble Whatman paper, nitrocellulose memebrane and gel as shown 
below: 
 
e. Close the cassette and place in the transfer chamber with the black side of 
the cassette facing the back side of the chamber.  
f. Place ice pack in the chamber. 
g. Place lid on the chamber and connect the leads to the power supply.  
h. Turn on the power supply and run at 120V for 2 hours. This can vary 
depending on the size of the protein of interest. 
2. Removal of transfer membrane: 
a. Turn off the power supply and disconnect leads from the power supply 
then remove the lid from the chamber. 
b. Remove the cassette from the chamber.  
c. With gloves on, remove the Whatman paper and gel and place the 
nitrocellulose membrane in a plastic dish.  
d. Add Ponceau S stain on the membrane and gently swirl.  
e. Drain off the remaining Ponceau S and save for reuse. 
f. Rinse the membrane with ddH20 to reduce the red background. Wrap 
membrane in saran wrap and scan image. 
g. Cut the membrane while protein bands are still visible at the desired 
molecular weight. 
h. Rotate membrane at room temperature in wash buffer until remaining 
Ponceau S has been removed. 
i. Incubate membrane for 1 hour with rotation in blocking solution.  
j. Incubate membrane with desired antibody diluted in blocking solution 
overnight at 4ºC. Membrane is placed face down into the solution on a 
glass plate covered in parafilm. To maintain a moist environment 
overnight, wet a small kimwipe and form it into a ball and place in each 
corner of the dish. Cover the dish with saran wrap. 
3. Immunodetection 
a. Wash the blots in wash buffer with gentle rotation for 5 minutes 3X. 
b. Incubate the blots for 1-2 hours with the appropriate secondary antibody 
diluted in blocking solution. 
c. Membrane is placed face down in solution on a glass plate covered with 
parafilm. Place moist kimwipes in each corner of the dish and cover the 
dish with saran wrap. 
d. Following the incubation, wash the membrane 3X for 5 minutes with wash 
buffer. 
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4. Enhanced Chemiluminescence Detection 
a. Mix ECl fluids “A” and “B” in a 1:1 ratio in a disposable Rohr tube. 
b. Place blots on saran wrap face up and apply ECL solution for 2 minutes.  
c. Dab off excess ECL on a kimwipe and place blots face down on a fresh 
piece of saran wrap and wrap tightly. 
d. Expose blot to film (time will vary depending on protein and antibody).  
e. Place film into developer (time will vary). 
f. Once image appears place film into fixer for 2 minutes. Wash with fresh 
water when complete. 
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Other Contributions to the Literature 
 
Published refereed papers 
 
1. Tryon LD, Crilly MJ, Hood DA. Effect of denervation on the regulation of 
mitochondrial transcription factor A expression in skeletal muscle. Am J Physiol 
Cell Physiol. 309(4): C228-38, 2015.  
2. Tryon L, Vainshtein A, Memme JM, Crilly MJ, Hood DA. Recent advances in 
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Research. 3(4): 161-171, 2014. 
Contribution to book chapter 
 
1. Hood DA, Tryon LD, Vainshtein A, Memme JM, Chen CW, Pauly M, Crilly MJ, 
Carter H. Exercise and the regulation of mitochondrial turnover. Prog Mol Biol 
Transl Sci. 135 (chapter 5): 99-127.  
Review paper (in preparation) 
 
1. Erlich AT, Tryon D, Crilly MJ, Memme JM, Moosavi Z, Oliveira A, Beyfuss K, 
Hood DA. Function of specialized regulatory proteins and signaling pathways in 
exercise-induced muscle mitochondrial biogenesis. Integrative Medicine 
Research [unpublished].  
Conference Proceedings and Presentations: 
 
1. Crilly MJ, Hood DA. The role of Nrf2 in the maintenance of mitochondrial 
content and running performance. Poster and abstract. (CSEP Annual Meeting, 
2015, Hamilton, Ontario).  
2. Crilly MJ, Hood DA. The influence of the Nrf2-Keap1 pathway on skeletal        
muscle and mitochondrial function. Poster and abstract. (MHAD, 2015, Toronto, 
Ontario) 
3. Crilly MJ, Hood DA. The role of Nrf2 in muscle phenotype and mitochondrial    
function. Poster and abstract. (Experimental Biology, 2015, Boston, MA) 
4. Tryon L, Crilly MJ, Hood DA. Mitochondrial transcription factor A regulation in 
response to rat skeletal muscle denervation. Poster and abstract. (CSEP Annual 
Meeting, 2014, St. Johns, Newfoundland) 
5. Crilly MJ, Carter HN, Tryon L and Hood DA. Relationship of muscle 
mitochondrial content and the Keap1-Nrf2 pathway. (CSEP Annual Meeting, 
2014, St. Johns, Newfoundland) 
6. Crilly MJ, Hood DA. Role of ROS in mediating denervation-induced muscle 
atrophy. Oral presentation and abstract. (OEP Annual Meeting, 2014, Barrie, 
Ontario) 
7. Carter HN, Crilly MJ, O’Leary MFN, Vainshtein A, Ostojic O, Hood DA.          
Chronic contractile activity induces a transcriptional profile to restore muscle      
mitochondrial homeostasis with age. Oral presentation and abstract. (CSEP         
Annual Meeting, 2013, Toronto, Ontario) 
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8. Memme JM, Crilly MJ, Tryon L, Iqbal S, Hood DA. Denervation-induced adapti
ons in autophagy and mitochondrial morphology protiens. Poster and abstract.      
(MHAD, 2013, Toronto, ON) 
9. Crilly MJ, Memme JM, Pastore SP, Hood DA. Circadian regulation of mitochon
drial content in skeletal muscle. Poster and abstract. (MHAD, 2013, Toronto, ON) 
 
 
 
 
 
 
